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A B S T R A C T
Background
Trachoma is the world’s leading infectious cause of blindness. In 1997 the World Health Organization (WHO) launched an Alliance
for the Global Elimination of Trachoma by the year 2020, based on the ’SAFE’ strategy (surgery, antibiotics, facial cleanliness and
environmental improvement).
Objectives
To assess the evidence supporting the antibiotic arm of the SAFE strategy by assessing the effects of antibiotics on both active trachoma
(primary objective) and on Chlamydia trachomatis (C. trachomatis) infection of the conjunctiva (secondary objective).
Search methods
We searched CENTRAL (which contains the Cochrane Eyes and Vision Group Trials Register) (The Cochrane Library 2010, Issue 11),
MEDLINE (January 1950 to December 2010), EMBASE (January 1980 to December 2010), the metaRegister of Controlled Trials
(mRCT) (www.controlled-trials.com) (December 2010) and ClinicalTrials.gov (www.clinicaltrials.gov) (December 2010). We used the
Science Citation Index to look for articles that cited the included studies. We searched the reference lists of identified articles and we
contacted authors and experts for details of further relevant studies. There were no language or date restrictions in the search for trials.
The electronic databases were last searched on 12 December 2010.
Selection criteria
We included randomised trials that satisfied either of two criteria: (a) trials in which topical or oral administration of an antibiotic was
compared to placebo or no treatment in people or communities with trachoma, (b) trials in which a topical antibiotic was compared with
an oral antibiotic in people or communities with trachoma. A subdivision of particular interest was trials in which topical tetracycline
or chlortetracycline and oral azithromycin were compared with each other, or in which one of these treatments was compared with
placebo or no treatment, as these are the two WHO recommended antibiotics. We considered individually randomised and cluster-
randomised trials separately.
Data collection and analysis
Two authors independently assessed trial quality and extracted data. We contacted investigators for missing data. Where appropriate,
the effect estimates from the individual studies (risk ratios) were pooled using a random-effects model.
1Antibiotics for trachoma (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Main results
A total of 14 trials randomised individuals with trachoma to oral antibiotic, topical antibiotic, both, or control (no treatment or placebo)
and were eligible for inclusion in this review (n = 3587). Overall, the quality of the evidence provided from these trials was low. Nine of
the trials compared antibiotic treatment to control. Most of the studies found a beneficial effect of treatment on active trachoma and
ocular chlamydial infection at three and 12 months follow up. There was considerable clinical and statistical heterogeneity between
trials, which meant that it was difficult to reliably estimate the size of the treatment effect. It is likely to be in the region of a 20%
relative risk reduction. Seven of the 14 trials compared the effectiveness of oral and topical antibiotics. There was no consistent evidence
as to whether oral or topical antibiotics were more effective, although one trial suggested that a single dose of oral azithromycin was
significantly more effective than unsupervised use of topical tetracycline
A further eight trials assessed the effectiveness of community-based treatment. In five trials antibiotic treatment was compared to no
(or delayed) treatment (57 communities), and in three trials oral antibiotic was compared to topical treatment (12 communities). The
quality of the evidence provided by these trials was variable but at least one trial was considered to provide high quality evidence. There
was evidence that community-based antibiotic treatment reduced the prevalence of active trachoma and ocular infection 12 months
after single-dose treatment. There was some evidence that oral azithromycin was more effective than topical tetracycline as a community
treatment. Data on adverse effects were not consistently reported however there were no reported serious adverse events associated with
treatment with oral azithromycin or topical tetracycline; in one sample survey of 671 people treated with azithromycin between 10%
and 15% experienced gastrointestinal adverse effects (nausea or vomiting, or both).
Authors’ conclusions
Antibiotic treatment reduces the risk of active trachoma and ocular chlamydial infection in people infected with C. trachomatis, but
we do not know for certain the size of the treatment effect in individuals. Mass antibiotic treatment with single-dose oral azithromycin
reduces the prevalence of active trachoma and ocular infection in communities.
P L A I N L A N G U A G E S U M M A R Y
Antibiotics reduce the prevalence of ocular infection with trachoma
Trachoma is common in people living in poor communities and is the most common infectious cause of vision loss. Repeated bouts
of conjunctivitis (inflammation of the membranes of the eyes) caused by Chlamydia infection eventually lead to scarring and inward
turning of the eyelid. The lashes rub on the cornea causing opacification and blindness. Antibiotics can be used to treat the Chlamydia
infection and may be given as an ointment or by mouth. This review included 14 trials in 3587 people with ocular trachoma and
eight community-based trials (67 communities). Antibiotic treatment reduce conjunctivitis caused by trachoma (’active trachoma’)
and ocular infection in individuals. Community-based trials provided evidence that azithromycin treatment reduces the prevalence of
active trachoma and ocular Chlamydia infection.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Antibiotic versus control for trachoma
Patient or population: patients with trachoma
Settings: individuals
Intervention: antibiotic
Comparison: control
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
control antibiotic
Active trachoma
Follow-up: 3 months
Medium risk population1 RR 0.78
(0.69 to 0.89)
1961
(9 studies)
⊕⊕©©
low2,3
800 per 1000 624 per 1000
(552 to 712)
Ocular chlamydia tra-
chomatis infection
Follow-up: 3 months
Medium risk population1 RR 0.81
(0.63 to 1.04)
297
(4 studies)
⊕⊕©©
low4,5
600 per 1000 486 per 1000
(378 to 624)
Active trachoma
Follow-up: 12 months
Medium risk population1 RR 0.74
(0.55 to 1)
1035
(4 studies)
⊕⊕©©
low6,7,8
750 per 1000 555 per 1000
(413 to 750)
Ocular chlamydial tra-
chomatis infection
Follow-up: 12 months
Medium risk population RR 0.25
(0.08 to 0.78)
129
(1 study)
⊕⊕©©
low9
190 per 1000 48 per 1000
(15 to 148)
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*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Median risk in control groups in included studies (rounded to nearest 10 per 1000)
2 Serious limitations in design: None of the trials reported methods to conceal the allocation. Two trials only attempted to mask the
assessment of active trachoma.
3 Serious inconsistency: Risk ratios ranged from 0.40 to 1.02.
4 Serious limitations in study design: None of the trials reported adequate allocation concealment. Three out of four trials masked
outcome assessment.
5 Serious imprecision: 95% confidence intervals include 1 (0.63 to 1.04)
6 Serious limitations in design: None of the trials reported allocation concealment or masking of outcome assessment.
7 Serious inconsistency: Risk ratios ranged from 0.50 to 1.05.
8 No downgrading for imprecision: The pooled estimate of effect is imprecise (confidence intervals 0.55 to 1). However, we felt that
this inconsistency probably arises due to limitation in study design and inconsistency and therefore did not additionally downgrade the
quality of evidence on the basis of this criteria.
9 Very serious limitations in study design: Only one small trial which did not report adequate methods of allocation concealment and did
not mask outcome assessment.
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B A C K G R O U N D
Description of the condition
Trachoma is the world’s leading infectious cause of blindness (
Resnikoff 2004). Active trachoma affects an estimated 41 million
people, the majority of them children (Mariotti 2009). About 1.3
million people are blind as a consequence of trachoma (Resnikoff
2004). It is a disease of poverty and is associated with poor water
supplies and sanitation.
There are two phases of trachoma. In the first phase, most fre-
quently seen in infancy and childhood, there are repeated attacks of
conjunctivitis caused by the organism Chlamydia trachomatis (C.
trachomatis). The conjunctivitis is characterised by the presence of
follicles on the under surface of the upper eyelid and by vascular
changes in active trachoma. Active trachoma is associated with dis-
charge from the eyes and nose that is particularly noticeable on the
faces of children, but the active stage may also be asymptomatic in
children and adults. When symptomatic, symptoms may persist
for months after the infection is cleared. C. trachomatis is trans-
mitted from child to child and from child to mother and back to
child through eye-finger-eye contacts, fomites and via eye-seeking
flies.
Repeated conjunctival infections over a number of years lead to the
secondphase of disease, characterised by scarring and shortening of
the upper eyelid. Ultimately, the lashes turn inwards to rub on the
cornea, causing pain, corneal abrasions and secondary infection.
Blindness results from corneal opacification. The blinding phase
affects women more commonly than men and typically starts in
adult life (Burton 2009). The treatment at this stage is surgery to
reposition the eyelid margin.
Description of the intervention
Active trachoma has been treated with antibiotics since the 1950s
and a variety of regimens have been used. The antibiotic can be
applied directly to the conjunctiva (topical) or taken orally (sys-
temic). Antibiotics applied topically are usually in the form of an
ointment and a variable amount is squeezed onto the inner surface
of the lower eyelid. This route gives a high concentration of the
antibiotic to the conjunctiva but a low dose to the nasopharynx,
which is also a reservoir for the organism. Ointments may cause
stinging eyes and temporary blurred vision, and they are difficult
to apply to small children.
Oral treatment gives a higher dose of antibiotic to sites of infec-
tion outside of the eye, but systemic antibiotics can have various
adverse effects in the person taking them. Bacteria anywhere in the
body may also develop antibiotic resistance. A full course of oral
treatment has a higher compliance rate than a course of topical
antibiotic.
Efforts in trachoma control have used various antibiotic treatment
regimens and have also been aimed at different subgroups within
a trachoma endemic area. Examples of subgroups are only those
individuals with clinical signs of disease (detected actively or pas-
sively), and active cases together with family contacts or high-risk
groups including school children. Because many individuals har-
bour infection without demonstrating physical signs, it has been
suggested that trachoma control cannot be achieved by antibiotic
treatment given only to subgroups of a trachoma endemic com-
munity (Bailey 1993; Kamiya 1956; Sutter 1983). This led to the
concept of community-based interventions, where all residents of
a community should receive treatment irrespective of disease sta-
tus.
The desired primary endpoint of any intervention against the ac-
tive disease is reduction of blindness but this could only be demon-
strated 20 to 30 years after the start of the intervention. The usual
surrogate outcome measure in trachoma intervention trials is clin-
ically active disease. In some trials a secondary endpoint is labora-
tory evidence of ocular C. trachomatis infection.
Why it is important to do this review
International interest in trachoma was given a boost in 1997 when
the WHO launched a new initiative for trachoma control, based
on the ’SAFE’ strategy. The components giving their name to the
acronym are surgery, antibiotics, facial cleanliness and environ-
mental improvement. Cochrane systematic reviews on surgery for
trichiasis (Yorston 2006), face washing (Ejere 2004) and environ-
mental sanitary interventions (Rabiu 2007) have also been com-
pleted.
The World Health Organization (WHO) recommended topical
treatment is 1% tetracycline ointment to both eyes, either twice
daily for six weeks or on five consecutive days each month for six
months. Compliance with this treatment is poor due to the side
effects of the ointment and the length of the treatment programme.
TheWHO recommended oral antibiotic is azithromycin, given as
a single dose of one gram in adults and 20mg/kg of body weight in
children. Azithromycin has lowplasma levels but high intracellular
concentrations and a long half-life. It has been shown to be an
effective treatment of genital chlamydial infections.
It is important to do this review to systematically evaluate the safety
and effectiveness of these recommended treatment regimens.
O B J E C T I V E S
The aim of this review is to assess the evidence in relation to the
antibiotic arm of the SAFE strategy by assessing the effects of
antibiotics on both active trachoma (primary objective) and on
C. trachomatis infection (secondary objective). In particular, when
this review was first published in 2002, the aim was to investigate
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the strength of evidence that antibiotics were more effective than
placebo in reducing disease and to compare the effects of oral
azithromycin with topical tetracycline.
These objectives were modified when the review was updated in
2010. It was decided to consider individually randomised and clus-
ter-randomised trials separately as we felt that they were address-
ing different questions and were likely to be measuring different
effects. The following two objectives were identified.
1. What is the effect of antibiotic treatment for individuals on
active trachoma and ocular C. trachomatis infection?
2. What is the effect of community treatment with antibiotics
on the prevalence of active trachoma and ocular C. trachomatis
infection?
M E T H O D S
Criteria for considering studies for this review
Types of studies
This review includes only randomised controlled trials (RCTs) of
antibiotic treatment for active trachoma. Clinical and community-
based trials were included in this review. In clinical trials the unit
of randomisation was the individual with active trachoma and
outcomes were reported at an individual level. In community-
based trials the unit of randomisation was a community, in which
some individuals had active trachoma, and outcomes may have
been reported at an individual or a community level.
Types of participants
Participants in the trials were people who were usually resident in
a trachoma endemic area.
Types of interventions
We included trials in which the interventions were:
1. topical or oral administration of an antibiotic at any dose or
frequency compared to placebo or no treatment;
2. topical administration of an antibiotic at any dose or frequency
compared to oral administration of an antibiotic at any dose or
frequency.
We excluded studies if the antibiotic was combined with an envi-
ronmental or educational intervention unless this component was
used uniformly across the trial and only the antibiotic treatment
varied in the different groups.
Types of outcome measures
We measured outcomes at three, 12 and 24 months after the start
of treatment. Three months was the time at which the maximum
effect on active trachoma was expected given that clinical signs
take several months to resolve after the clearance of infection. We
selected 12 months to represent the period during which recur-
rence of infection or relapse would be most likely to occur, and
we selected 24 months to reflect the expected long-term result of
one course of treatment. A course of treatment may be a single or
multiple doses of an oral antibiotic or interrupted applications of
a topical antibiotic applied over six weeks to several months.
In order to take into account the fact that studies may not have
collected outcomes at those exact times, we defined the following
ranges for each:
• three months, i.e. outcomes measured before six months;
• 12 months, i.e. outcomes measured between six months
and 18 months;
• 24 months, i.e. outcomes measured after 18 months.
If more than one outcome measurement was available, then we
selected the nearest measurement to three, 12 or 24 months.
Primary outcomes
The primary outcome for this review was active trachoma. There
are five main trachoma grading scales (Dawson 1975b; Dawson
1981b; MacCallan 1936; Thylefors 1987; WHO 1962). All these
scales, except for MacCallan, quantify the number of follicles and
the degree of vascular engorgement of the under surface of the
upper eyelid as seen with low magnification (usually x 2.5). The
Dawson scales subdivide the follicular and papillary activity as F
0 to 3 and P 0 to 3. The Thylefors scale is a simplified version
defining active trachoma by the grades TF (mild-moderate) and
TI (intense). The MacCallan scale is not directly comparable with
the other scales as scarring is included as an indicator of active
disease. The four more recent scales are broadly comparable. A
minor inconsistency between them is that Dawson’s F1 is defined
as five or fewer follicles in zones two and three, and F2 as “more
than 5 follicles in zones 2 and 3 together, but less than 5 in zone
3”; whereas TF is five or more follicles in zones two and three.
This means that the divisions between F1 and F2 and ’not TF’
and TF do not quite coincide.
In this review we defined the absence of active trachoma as:
• not TF and not TI (Thylefors scale);
• (P0 or P1 or P2) AND (F0 or F1) (WHO and Dawson
scales).
We defined active trachoma as TF, TI, or both, in the Thylefors
scale; or any other grade for P or F in theWHO or Dawson scales.
Secondary outcomes
The secondary outcome was a positive test for C. trachomatis in-
fection. A variety of tests have been used to demonstrate presence
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of the pathogen. Historically, staining of conjunctival cells to show
inclusion bodies was the firstmethod of identifying infection. This
was followed by culture of the organism, which was time consum-
ing and lacking in sensitivity. The demonstration of antigen by
various antibody staining methods followed, and finally identifi-
cation of chlamydial DNA by various amplification methods. The
tests, in order of increasing sensitivity, are:
1. culture by C. trachomatis isolation in eggs or tissue culture;
2. staining of conjunctival smears with giemsa or iodine;
3. direct fluorescent antibody cytology;
4. indirect enzyme immunoassay;
5. DNA hybridisation;
6. DNA amplification with the ligase chain reaction;
7. DNA amplification with the polymerase chain reaction.
We recorded adverse effects, if reported.
Search methods for identification of studies
Electronic searches
We searched the Cochrane Central Register of Controlled Tri-
als (CENTRAL) 2010, Issue 11, part of The Cochrane Library.
www.thecochranelibrary.com (accessed 12 December 2010),
MEDLINE (January 1950 to December 2010), EMBASE (Jan-
uary 1980 to December 2010), the metaRegister of Controlled
Trials (mRCT) (www.controlled-trials.com) (December 2010)
and ClinicalTrials.gov (www.clinicaltrials.gov) (December 2010).
There were no language or date restrictions in the search for trials.
The electronic databases were last searched on 12December 2010.
See: Appendices for details of search strategies for CENTRAL
(Appendix 1),MEDLINE (Appendix 2), EMBASE (Appendix 3),
mRCT (Appendix 4) and ClinicalTrials.gov (Appendix 5).
Searching other resources
We used the Science Citation Index to search for articles that cited
the included studies. We searched the reference lists of identified
articles for any other potentially relevant studies.We also contacted
experts in the field, either directly or through the membership
of the WHO workshops, requesting information on unpublished
trials.
Data collection and analysis
Selection of studies
For the first publication of this review, one author assessed the
titles identified from the initial searches and selected all titles that
made reference to treatment for trachoma. When the review was
updated in 2005, and again in 2011, two authors screened the
search results. The searches also found references to genital C.
trachomatis infections and to laboratory tests on C. trachomatis.
We excluded titles that clearly referred to either of these groups
at the first viewing. Two authors independently obtained the full
copies of all possibly relevant papers and assessed them according
to the ’Criteria for considering studies for this review’. We assessed
the trials meeting these criteria for quality.
Data extraction and management
Two authors independently extracted data. Discrepancies were re-
solved before entry into Review Manager 5 (RevMan 2008).
For the update of the review in 2011, JE checked the original data
collection and entry. Appendix 6 summarises the changes that were
made. For the new trials that were identified, two authors (JE,
AWS) extracted data independently and resolved discrepancies by
discussion. Data were entered by both authors onto two spread-
sheets and cross-checked. Data were cut and pasted into RevMan
from the spreadsheet (JE).
Assessment of risk of bias in included studies
This was a new feature for the update in 2011. We assessed the
risk of bias using the Cochrane Collaboration’s tool for assessing
the risk of bias (Higgins 2008a).
We assessed the extent to which bias could have been introduced
in the following aspects of study design and execution: sequence
generation, allocation concealment, blinding (masking), incom-
plete outcome data and selective outcome reporting.
We did not assess sequence generation and allocation concealment
for cluster-randomised studies but considered two additional cri-
teria: recruitment bias and baseline imbalances (Higgins 2008b).
Two authors (JE, AWS) independently assessed risk of bias, com-
pared results and resolved discrepancies by discussion.
Measures of treatment effect
The primary outcome for the review was active trachoma and the
secondary outcome was ocular C. trachomatis infection. Both of
these are dichotomous (adverse) outcomes and our preferred effect
measure was the risk ratio.
Unit of analysis issues
This review includes trials in which individuals were randomly
allocated to treatment and trials in which communities were the
unit of allocation (cluster-randomised trials). A correct analysis
of cluster-randomised trials includes an adjustment for the fact
that people within a cluster tend to be more similar to each other
than to people from other clusters i.e. the observations are not
independent. The effect of cluster-randomisation is to increase the
size of standard errors and hence widen the confidence intervals
comparedwith a study of the same size using individual participant
randomisation (Donner 1982).
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For the update in 2011, our preferredmethodof analysis of cluster-
randomised studies was as follows: for those studies that reported
the effect measure using an analysis that properly accounted for
the cluster design, we planned to enter and pool data from differ-
ent studies using the generic-inverse variance method in RevMan.
However, we were aware that cluster-randomised trials are not al-
ways analysed and reported appropriately. For those studies that
did not report such an effect measure we planned to perform an
approximate analysis (Higgins 2008b) as follows:
• calculate a ’design effect’ of 1 + (M - 1) ICC (where ICC =
intra-cluster correlation coefficient and M = average cluster size);
• multiply the standard error of an analysis at the individual
level by the square root of the design effect.
Estimates from the literature suggest that the ICC can vary from
0.05 to 0.2 (Katz 1988; West 1991). We planned sensitivity anal-
yses using iCC estimates of 0.05. 0.1 and 0.2.
Dealing with missing data
The clinical need to change or discontinue antibiotic therapy (for
an individual undergoing treatment for a single episode of infec-
tion of disease, or a community undergoing a single round of mass
treatment) is likely to be rare. This reduces the potential problems
associated with performing the analysis on an intention-to-treat
basis. More serious problems may arise from losses to follow up
and non-compliance. Some of the trials have been done in largely
transient populations in which losses to follow up rapidly accu-
mulate as people move on. Such losses were assumed to be inde-
pendent of the outcome measures, therefore we did not exclude
studies on this basis.
Assessment of heterogeneity
We assessed heterogeneity by considering clinical and study design
differences between trials and by examining the forest plots. We
also considered statistical measures of heterogeneity such as the χ
2 test and I2 statistic.
Assessment of reporting biases
As less than 10 trials were included in the meta-analyses in this
version of the review we did not assess publication bias. In future
updates that include more trials, we will assess the possibility of
small study effects, including publication bias, using a funnel plot
(plotting the risk ratio along the x axis versus standard error along
the y axis).
We did not judge the possibility of selective reporting of outcomes
to be a problem in most of the included trials because the two
main outcomes of this review, active trachoma and C. trachomatis
infection, were usually reported.
We included all trials irrespective of the language of publication,
however we cannot exclude the possibility that negative trials have
been published in less accessible journals (see publication bias
above).
We did not find any evidence of multiple (duplicate) reporting
publication bias. Data from one of our included trials (ACT 1999
The Gambia) were published twice, with ocular C. trachomatis
infection being the focus of one publication and active trachoma
the focus of the other, but the relationship of the data was clear
from the publications.
Data synthesis
In the original review, the review authors pooled outcomes from
community-based trials in which non-affected and affected cases
were treated with outcomes from individual-based trials in which
only affected cases were treated. The original protocol planned but
did not carry out a sensitivity analysis to determine the effect of
using only data from cases that were active at baseline.
In the update, we considered these community-based and indi-
vidually randomised trials separately as they are asking different
questions and are likely to be estimating different treatment ef-
fects.
Where appropriate, data were pooled using a random-effects
model. If there were three trials or less we used a fixed-effectmodel.
In cases where there was substantial heterogeneity or inconsistency,
that is the individual study estimates were different sides of the
null line and/or confidence intervals did not overlap, with corre-
sponding high levels of I2 we did not pool the results.
Subgroup analysis and investigation of heterogeneity
We considered type of antibiotic (oral or topical) to be a potential
source of clinical heterogeneity. This subgroup analysis was not
specified explicitly but was implied in the objectives of the orig-
inal protocol which were to consider oral and topical antibiotics
separately, in particular oral azithromycin and topical tetracycline.
A further subgroup analysis considered just those trials in which
communities were randomised to oral azithromycin, topical tetra-
cycline, or both, where the antibiotic was administered using regi-
mens consistent withWHOguidelines current in 2010, compared
either to each other, placebo or no treatment.
Sensitivity analysis
As set out above under ’unit of analysis issues’, we considered
the possible effect of assumptions about the size of the intra-class
correlation coefficient (ICC) on the results.
R E S U L T S
Description of studies
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The characteristics of the included studies and reasons for exclu-
sion of studies are detailed in the ’Characteristics of included stud-
ies’ and ’Characteristics of excluded studies’ tables.
Results of the search
Details of the original searches for previous versions of this review
are in Appendix 7. The electronic searches were updated in De-
cember 2010. After de-duplication, the search identified a total of
341 references. The Trials Search Co-ordinator scanned the search
results and removed 251 references which were not relevant to the
scope of the review. Two authors independently reviewed the re-
maining 90 references and three new studies were identified (Atik
2006; Lee 2007; TANA 2009). Three studies previously classified
as excluded studies were considered to be eligible for inclusion
(Bailey 1993; Chidambaram 2006; Resnikoff 1995). One new re-
port with relevant data for ACT 1999 The Gambia was identified.
Fourteen individually randomised studies were included in this re-
view (Attiah 1973; Bailey 1993; Bowman 2000; Cochereau 2007;
Darougar 1980; Dawson 1969 Sherman; Dawson 1969 Stewart;
Dawson 1997; Foster 1966; Hoshiwara 1973; Peach 1986; Shukla
1966; Tabbara 1996; Woolridge 1967). The citations Dawson
1969 Sherman and Dawson 1969 Stewart refer to two arms of the
same trial, which were conducted in different schools. As the re-
sults were reported separately in the paper, they have been treated
as separate studies.
Eight community-based studies were included in this review (ACT
1999 Egypt; ACT 1999 Tanzania; ACT 1999 The Gambia; Atik
2006; Chidambaram 2006; Lee 2007; Resnikoff 1995; TANA
2009). The three ACT citations used the same protocol, which
was applied in different countries and reported in the same article.
Chidambaram 2006, Lee 2007 and TANA 2009 used communi-
ties with ’delayed treatment’ as a comparator group. Although this
had the disadvantage that baseline data were not available, it is an
ethical solution to community randomisation.
Included studies
Types of participants
In individually randomised studies, all participants had active tra-
choma in at least one eye. The groups described were children aged
six to 12 years in Egypt (Attiah 1973), people aged nine months
and older in The Gambia (Bailey 1993), children aged six months
to 10 years in The Gambia (Bowman 2000), children age one to
10 years in Pakistan and Guinea-Conakry (Cochereau 2007), pre-
school children in Iran (Darougar 1980), boarding school residents
aged 12 to 21 years in USA (Dawson 1969 Sherman; Dawson
1969 Stewart), children aged two to 10 years in Egypt (Dawson
1997), boarding school residents aged eight to 20 years in USA
(Foster 1966), boarding school residents aged seven to 13 years in
USA (Hoshiwara 1973), children under 21 years in northern Aus-
tralia (Peach 1986), school children aged five to 13 years in India
(Shukla 1966), children aged seven to 14 years in Saudi Arabia
(Tabbara 1996), primary school children in Taiwan (Woolridge
1967).
In the community-based studies, three studies (ACT 1999 Egypt;
ACT 1999 Tanzania; ACT 1999 The Gambia) included all resi-
dents of the study villages irrespective of age or trachoma status.
Chidambaram 2006 and TANA 2009 offered treatment to every-
one over the age of one year but data were reported for children
aged one to five and one to 10 years old respectively. The settings
were Egypt, Ethiopia, Saudi Arabia, The Gambia and Tanzania.
One study (Atik 2006) included all residents of study villages who
were over the age of six months; the setting was Vietnam. In three
studies, carried out in Ethiopia (Chidambaram 2006; Lee 2007)
and Mali (Resnikoff 1995), only children aged one to five years
were examined but all residents of treated villages were offered
treatment.
Types of intervention
There were various treatment strategies applied over periods of
three weeks to 12 months. Table 1 summarises the different treat-
ment schedules for the individually randomised studies.
Eleven trials investigated oral antibiotics (Bowman 2000; Bailey
1993; Cochereau 2007; Darougar 1980; Dawson 1969 Sherman;
Dawson 1969 Stewart; Dawson 1997; Foster 1966; Hoshiwara
1973; Shukla 1966; Tabbara 1996). Five trials used azithromy-
cin 20 mg/kg (Bailey 1993; Bowman 2000; Cochereau 2007;
Dawson 1997; Tabbara 1996). Other oral antibiotics included
doxycycline (Darougar 1980; Hoshiwara 1973), trisulphapyrim-
idines (Dawson 1969 Sherman; Dawson 1969 Stewart), sul-
phamethoxypyridazine (Foster 1966) and sulphadimethoxine (
Shukla 1966).
Almost all of the included individually-randomised trials had
a treatment arm with topical antibiotics (the exception was
Hoshiwara 1973.) Almost all of these trials of topical antibiotic
used tetracycline or oxytetracycline. Most used 1% formulations.
One trial used 0.25% (Attiah 1973) and in one trial people with
’severe disease’ were given erythromycin 250 mg four times daily
for two weeks in addition to topical tetracycline (Bailey 1993).
A couple of trials did not report the dose (Bowman 2000; Peach
1986).Dawson 1997 used tetracycline 1%with polymyxin10,000
units/g. Shukla 1966 used sulphafurazole 15%. There was con-
siderable variation in the treatment schedules used. Topical treat-
ment was applied one to four times daily, for one to seven days
over a six week to 12 month period. Cochereau 2007 was the only
trial to use topical azithromycin 1.5% on a two-day and three-day
treatment schedule.
Some trials compared oral and topical treatments (Bailey 1993;
Bowman 2000; Cochereau 2007; Darougar 1980; Dawson 1969
Sherman; Dawson 1969 Stewart; Dawson 1997; Foster 1966;
Shukla 1966; Tabbara 1996). In three of these trials there was also
an untreated control group (Darougar 1980; Foster 1966; Shukla
1966).
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Table 2 summarises the treatments used in the cluster-randomised
studies. The majority of the cluster-randomised trials investigated
azithromycin 20 mg/kg and this was compared to tetracycline
or oxytetracycline 1% (ACT 1999 Egypt; ACT 1999 Tanzania;
ACT 1999 The Gambia; Atik 2006). One trial (Atik 2006) as-
sessed the effect of targeted treatment (with azithromycin 20 mg/
kg) on schoolchildren with active trachoma, aged five to 15 years,
plus their family members within the selected clusters rather than
mass treatment of the entire cluster. One trial compared oxyte-
tracycline 1% against no treatment (Resnikoff 1995). Three trials
compared azithromycin 20 mg/kg against no (delayed) treatment
(Chidambaram 2006; Lee 2007; TANA 2009). Specific exclusion
criteria were usually given for pregnant women who were given
either oral erythromycin or topical tetracycline instead of azithro-
mycin.
Types of outcome measures
Most trials used active trachoma as the main outcome measure,
the exceptions being Lee 2007, Chidambaram 2006 and TANA
2009 which focused on ocular chlamydial infection. The trachoma
grading scales used after 1962 do not have scarring as a feature of
active trachoma and so the underlying principles in the grades are
more or less equivalent in all of the studies, using only the presence
of follicles and papillae for diagnosis of active disease.
The secondary outcome measure was presence of C. trachomatis.
The laboratory tests used were culture in McCoy cells, one to five
identifiable inclusions per 100 to 1000 cells, elementary bodies≤
200 or ≥ 200 on conjunctival smear immunofluorescence, poly-
merase chain reaction (PCR) and ligase chain reaction (LCR).
Follow up
Most studies reported outcomes at three months. Fewer trials re-
ported outcomes at 12 months and only one trial reported out-
comes at 24 months.
Excluded studies
See the ’Characteristics of excluded studies’ table for information
on excluded studies, including reasons for exclusion.
Risk of bias in included studies
See Figure 1 and Figure 2. There were 14 individually randomised
trials included in this review and eight cluster-randomised trials.
We did not assess sequence generation and allocation concealment
for cluster-randomised studies but considered two additional cri-
teria: recruitment bias and baseline imbalances (see other potential
sources of bias).
Figure 1. Methodological quality graph: review authors’ judgements about each methodological quality
item presented as percentages across all included studies.
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Figure 2. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study.
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Allocation
Sequence generation and allocation concealment were poorly de-
scribed, with only one trial (Bowman 2000) reporting adequate
methods for both of these criteria. Dawson 1997 and Woolridge
1967 reported adequate sequence generation but not allocation
concealment, which was likely to be a more important source of
bias.
Blinding
Assessment of ocular C. trachomatis infection is relatively easy to
mask as it is straightforward to anonymise laboratory samples.
Eleven out of 14 studies that reported ocular chlamydial infec-
tion also reported masking the assessment of the laboratory sam-
ples. Clinical assessments of trachoma are more difficult to mask,
especially in the cluster-randomised studies where one commu-
nity received treatment and another did not, or in cases where
the treatments differed for example oral versus topical antibiotic.
Only five studies reported efforts to mask the assessment of active
trachoma (Bailey 1993; Bowman 2000; Cochereau 2007; Dawson
1969 Sherman; Dawson 1969 Stewart).
Incomplete outcome data
Only three studies provided data suggesting that incomplete out-
come data were unlikely to bias the results, that is they re-
ported high follow-up rates which were equal between interven-
tion groups (Bailey 1993; Dawson 1997; TANA 2009).
Selective reporting
There was little suggestion of selective outcome reporting. Table
3 and Table 4 show the outcome reporting grid. In most cases,
where an outcome was not reported it was because the study follow
up was not conducted at that time point or “Not mentioned but
clinical judgement says unlikely to have been measured”, which is
unlikely to introduce bias. Three trials did not report active tra-
choma. For Chidambaram 2006 and TANA 2009, data on active
trachoma were collected and not reported; the authors have sup-
plied unpublished data on active trachoma for TANA 2009. For
Lee 2007 the focus of the study was the presence of C. trachomatis
DNA on flies and in the eyes of children, so it was plausible that a
clinical assessment was not done. Nine trials (out of a total of 21
included studies) did not report ocularC. trachomatis infection but
there was nothing in the reports of these studies to suggest that the
data had been collected and not reported. In one trial Cochereau
2007 it was clear that data on ocular infection had been collected
but not reported.
All studies (with the exception of Lee 2007) reported outcomes
at three months. Thirteen (out of 21) trials reported outcomes
at 12 months. Only one trial reported 24 months outcomes
for both treatment and control groups (Atik 2006), although
Chidambaram 2006 reported outcomes for the treated commu-
nities only at 24 months. Again, there was no suggestion from the
published reports that the non-publication of outcomes at 12 or
24 months was related to study results (Table 3, Table 4).
Other potential sources of bias
Recruitment bias can occur when individuals are recruited to the
trial after the clusters have been randomised as the knowledge of
whether each cluster is an ‘intervention’ or ‘control’ cluster could
affect the types of participants recruited (Higgins 2008b). None
of the included studies discussed this issue.
When small numbers of clusters are randomised, there is a possibil-
ity of chance baseline imbalance between the randomised groups
in terms of either the clusters or the individuals (Higgins 2008b).
This was a particular problem with the cluster-randomised trials
included in this review. Four of the trials randomised only two
communities to treatment or control (ACT 1999 Egypt; ACT
1999 Tanzania; Atik 2006; Resnikoff 1995) and one trial ran-
domised only six communities (three in each group) to treatment
or control (Lee 2007). Only two studies were of a reasonable size
(Chidambaram 2006: 15 communities; TANA 2009: 24 commu-
nities). In ACT 1999 The Gambia eight communities were pair
matched.
Reporting of the baseline comparability of clusters or statistical ad-
justment for baseline characteristics (ACT 1999 Egypt; ACT1999
Tanzania; Lee 2007) can help reduce concern about the effects of
baseline imbalances, however it is difficult to interpret differences
in treatment effect between only two communities because there
may be some other unknown confounding factor that explains the
difference in effect.
Effects of interventions
See: Summary of findings for the main comparison Antibiotic
versus control for trachoma: individuals; Summary of findings
2 Oral versus topical antibiotic for trachoma: individuals;
Summary of findings 3 Oral azithromycin compared to control
for trachoma: communities; Summary of findings 4 Oral
azithromycin compared to topical tetracycline for trachoma:
communities
What is the effect of antibiotic treatment of the individual
on active trachoma and ocular C. trachomatis infection?
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Antibiotic versus control (placebo)
Analysis 1.1 shows the effect of any antibiotic treatment on active
trachoma at three months. Nine trials randomising 1961 people
contributed to this analysis. There was considerable heterogeneity
between trials (I2 = 73%). The treatment effects observed in the
different trials ranged from a risk ratio of 0.40 (95% CI 0.20 to
0.79) (Dawson 1969 Stewart) to a risk ratio of 1.02 (95% CI 0.83
to 1.25) (Darougar 1980). However, most of the trials suggested
an apparent beneficial effect of treatment on active trachoma mea-
sured at three months follow up. The pooled risk ratio was 0.78
(95% CI 0.69 to 0.89).
Analysis 1.2 shows the effect of any antibiotic treatment on ocular
C. trachomatis infection at three months. Fewer trials contributed
to this analysis (four trials, n = 297). However, in contrast to the
effect on active trachoma there was no evidence of any heterogene-
ity in treatment effect between trials (I2 = 0). The treatment effect
appeared to be of a similar order of effect as for active trachoma
but did not achieve conventional levels of statistical significance
(pooled risk ratio of 0.81, 95% CI 0.63 to 1.04).
Analysis 1.3 shows the effect of any antibiotic treatment on active
trachoma at 12 months. Four trials randomising 1035 people con-
tributed to this analysis. Again there was evidence of considerable
heterogeneity between trials (I2 = 90%). The treatment effects
observed in the different trials ranged from a risk ratio of 0.50
(95% CI 0.41 to 0.62) (Shukla 1966) to a risk ratio of 1.05 (95%
CI 0.88 to 1.24) (Foster 1966). However, three of the four trials
showed a statistically significant beneficial effect of treatment on
active trachoma measured at 12 months follow up. The pooled
risk ratio was 0.74 (95% CI 0.55 to 1.00).
Analysis 1.4 shows the effect of any antibiotic treatment on C.
trachomatis infection at 12 months. Only one trial provided data
on ocular chlamydial infection at 12 months (Darougar 1980).
The effect was strong with a risk ratio of 0.25. Although this
was statistically significant the estimate of treatment effect was
imprecise with a wide confidence interval (0.08 to 0.78), reflecting
the small sample size of the trial.
One source of clinical heterogeneity in these trials was whether
oral or topical antibiotic was used. One of the objectives of the
review was to compare oral and topical treatment, in particular
oral azithromycin and topical tetracycline.
Analysis 2.1 shows the results separately for the trials that con-
sidered oral antibiotic versus control and the trials that consid-
ered topical antibiotic versus control on active trachoma at three
months. Although statistical heterogeneity was reduced by con-
sidering these trials separately, there remained substantial hetero-
geneity (I2 of 60% and 68%). The pooled estimate of treatment
effect for oral antibiotics on active trachoma at three months was
0.81 (95% CI 0.67 to 0.97) and for topical antibiotics was 0.82
(0.72 to 0.92). A similar picture was seen for active trachoma at
12 months (Analysis 2.3). There were not enough data to make
a reliable comparison of the effects of oral and topical antibiotics
versus control on C. trachomatis infection (Analysis 2.2; Analysis
2.4).
Subgroup analyses such as these can be misleading because there
may be other reasons for differences between trials apart from the
type of antibiotic used. Direct comparison of oral versus topical
antibiotic within trials is a more reliable estimate of relative effect.
Oral versus topical antibiotic
Analysis 3.1 shows the effect of oral versus topical antibiotic on
active trachoma at threemonths fromwithin-trial comparisons (six
trials, n = 953). There was considerable statistical heterogeneity
(I2 = 63%). The estimates of effect were spread across the null
line with three trials reporting a beneficial effect of oral antibiotics
and three trials reporting a beneficial effect of topical antibiotics.
Three of the six trials (Darougar 1980; Dawson 1997; Foster
1966) had findings consistent with a hypothesis of no difference in
effect. Similarly for active trachoma at 12 months (Analysis 3.3),
C. trachomatis infection at three (Analysis 3.2) and 12 months
(Analysis 3.4), there was no consistent evidence as to whether oral
or topical antibiotics were more effective.
Examining the trials for clinical heterogeneity suggested that the
interventions used in Bowman 2000 were different. In particu-
lar, this study focused on “practical operational conditions” which
meant that the topical treatments were unsupervised. Excluding
this trial from the analyses substantially reduced the observed in-
consistency (I2 = 0) with a pooled risk ratio for the remaining
five included trials of 1.04 (95% CI 0.94 to 1.16). Similar im-
provements in consistency were seen when Bowman 2000 was
excluded from the 12 months analyses (i2 changed from 56% to
29%, pooled risk ratio 1.01 (95% CI 0.85 to 1.20).
Analysis 4.1, Analysis 4.2, Analysis 4.3 and Analysis 4.4 show
the specific comparison between oral azithromycin and topical
tetracycline for active trachoma and C. trachomatis infection at
three and 12 months. There was considerable heterogeneity in
the results of these studies for active trachoma (Analysis 4.1). As
before, excluding Bowman 2000 from the analyses substantially
reduced the inconsistency (I2 = 0) and the pooled risk ratio of
the two remaining trials was 1.01 (95% CI 0.80 to 1.28). Only
two trials reported data at 12 months. Bowman 2000 reported
a beneficial effect of azithromycin compared to tetracycline (risk
ratio 0.66, 95%CI 0.45 to 0.98). Dawson 1997 reported a smaller
effect which was not statistically significant (risk ratio 0.90, 95%
CI 0.65 to 1.23).
Data from Bailey 1993 have not been included in the graphi-
cal analyses because they compared oral antibiotic (single-dose
azithromycin) with a combination of topical/oral antibiotic (top-
ical tetracycline with oral erythromycin for severe cases). A to-
tal of 194 people with active disease were randomly allocated to
treatment, 97 in each group. Approximately 60% of these people
were antigen positive at baseline. At 26 weeks 21/97 had active
disease in the azithromycin group and 27/97 in the tetracycline/
erythromycin group (risk ratio 0.78 95% CI 0.47 to 1.28). Ap-
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proximately 42% of each group was antigen positive. Data from
Cochereau 2007 also have not been included in the meta-analyses
because they compared oral azithromycin with two regimens of
topical azithromycin and treated people accompanying the chil-
dren to the treatment centre. They found that trachoma resolved
in 93.0%, 96.3% and 9.6.6% of the two-day group, three-day
group and oral treatment group 60 days after treatment.
What is the effect of community treatment with antibiotics
on active trachoma and ocular C. trachomatis infection?
All the cluster-randomised community-based trials discussed in
this section compared oral azithromycin to control or oral azithro-
mycin to topical tetracycline.
Antibiotic versus control (placebo)
Four community-based trials compared azithromycin versus no
treatment (Atik 2006; Chidambaram 2006; Lee 2007; TANA
2009). None of these trials reported outcomes at three months.
Atik 2006 published data on active trachoma at 12 months and
unpublished data were supplied for TANA 2009 (Analysis 5.1).
The two trials reported very different results. Atik 2006 reported a
non-significant increased risk of active trachoma in the community
treated with azithromycin (risk ratio 1.14, 95% CI 0.67 to 1.94)
whereas in TANA 2009, communities receiving mass treatment
with azithromycin had a reduced prevalence of active trachoma
in children 12 months after treatment (risk ratio 0.58, 95% CI
0.52, 0.65). It is difficult to explain the differences between the
two studies, however, Atik 2006 only compared two communities
compared to the 24 randomised inTANA 2009.Of the two studies
TANA 2009 was judged to be at lower risk of bias (Figure 2).
These analyses do not take into account the cluster design of the
studies. Data from TANA 2009 suggested an intra-cluster corre-
lation coefficient (ICC) of approximately 0.06. Adjusting the re-
sults of TANA 2009 for this ICC gave a 95% CI 0.47 to 0.72. In
fact the results of this study were reasonably robust to assumptions
about the ICC; adjusting for an ICC of 0.2 gave a 95% CI of 0.41
to 0.83.
Atik 2006, Chidambaram 2006, Lee 2007 and TANA 2009 re-
ported C. trachomatis infection at 12 months (Analysis 5.2). In
all four studies communities treated with azithromycin were less
likely to have C. trachomatis infection at 12 months compared to
untreated communities. These studies gave different estimates of
effect (0.61 in Atik 2006, 0.49 in Chidambaram 2006, 0.04 in
Lee 2007 and 0.32 in TANA 2009). The pooled risk ratio was
0.35 (95% CI 0.21 to 0.60). Although it is likely that the size
of the pooled effect estimate is unreliable, given the differences
between the studies, all of the studies indicated a statistically sig-
nificant beneficial effect of antibiotic treatment on C. trachomatis
infection.
The conclusions did not change as a result of adjusting for the extra
variation introduced by the cluster design of the studies. Adjusting
for an ICC of 0.2 gave a confidence interval for the pooled risk
ratio of 0.20 to 0.63.
Data from Resnikoff 1995 are not included in the forest plots
as it was difficult to extract data in a suitable format. The study
randomly allocated four villages in factorial fashion to treatment
with 1% oxytetracycline or health education. Individuals treated
with tetracycline experienced a higher cure rate than people who
were not and communities treated with tetracycline experienced a
lower incidence and prevalence of the disease.
Oral versus topical antibiotic
Only one study compared oral and topical community-based treat-
ment for trachoma, the ’Azithromycin in Control of Trachoma’
study (ACT). As this study took place in three different countries
in Africa (Egypt, The Gambia and Tanzania), it is included in the
analyses as three studies.
Even though all three studies had the same interventions and the
one study protocol there was still considerable heterogeneity of
effect. However, it must be remembered that in two locations only
two communities were randomised to oral versus topical treatment
(ACT 1999 Egypt; ACT 1999 Tanzania).
Analyses 6.1 to 6.4 show the effect of community-based treat-
ment with azithromycin versus topical tetracycline (Analysis 6.1;
Analysis 6.2; Analysis 6.3; Analysis 6.4). In ACT 1999 Egypt and
ACT 1999 The Gambia there was some evidence that azithromy-
cin was more effective than topical tetracycline in reducing the
risk of active trachoma and C. trachomatis infection at three and
12 months. However, these results were not very robust to as-
sumptions about the ICC. Adjusting for an ICC of 0.05 resulted
in confidence intervals including one for all the results. In ACT
1999 Tanzania, the findings were less consistent, with a risk ratio
greater than one (favouring topical treatment) for active trachoma
and C. trachomatis infection at 12 months and risk ratio less than
one (favouring oral treatment) forC. trachomatis infection at three
months.
Adverse effects
Table 5 summarises the information on adverse effects reported
in the included studies. Data on adverse effects were sparsely re-
ported. In 12 of the 22 included studies there was no mention of
adverse effects in the study report. In TANA 2009 data on adverse
effects were collected systematically: 96/671 individuals treated
with azithromycin reported an adverse effect of treatment (14.3%,
95% CI 11.7% to 17.2%); 72 of these (10.7% 95% CI 8.5%
to 13.3) were gastrointestinal (abdominal pain, vomiting, nau-
sea, diarrhoea, constipation and related issues); no serious adverse
events were recorded in this study. A specific analysis of childhood
mortality suggested that azithromycin treatment reduced the rate
of childhood mortality in these communities. The mortality rate
for children aged one to nine years was 4.1 per 1000 person-years
14Antibiotics for trachoma (Review)
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(95% CI 3.0 to 5.7) in the treated communities compared to 8.3
per 1000 person-years (95%CI 5.3 to 13.1) in the untreated com-
munities.
A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Oral versus topical antibiotic for trachoma
Patient or population: patients with trachoma
Settings: individuals
Intervention: oral antibiotic
Comparison: topical antibiotic
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
topical antibiotic oral antibiotic
Active trachoma
Follow-up: 3 months
Medium risk population1 RR 0.98
(0.82 to 1.18)
953
(6 studies)
⊕⊕⊕©
moderate2
Pooled RR excluding
Bowman 2000 RR 1.04
(95% CI 0.94, 1.16). 3578 per 1000 566 per 1000
(474 to 682)
Ocular chlamydia tra-
chomatis infection
Follow-up: 3 months
See comment See comment Not estimable 298
(3 studies)
⊕©©©
very low4,5
Darougar 1980 RR 6.
05 (95% CI 0.78, 46.95)
; Dawson 1997 RR 0.
57 (0.14, 2.30); Tabbara
1996 RR 1.30 (0.41,4.
11)
Active trachoma
Follow-up: 12 months
Medium risk population1 RR 0.93
(0.75 to 1.15)
886
(5 studies)
⊕©©©
very low6,7
Pooled RR excluding
Bowman 2000 RR 1.01
(95% CI 0.85, 1.20). 3565 per 1000 525 per 1000
(424 to 650)
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Ocular chlamydia tra-
chomatis infection
Follow-up: 12 months
See comment See comment Not estimable 220
(2 studies)
⊕©©©
very low
Darougar 1980 RR 2.59
(95% CI 0.28, 23.88);
Dawson 1997 RR 0.50
(0.18, 1.43)
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Median risk in control groups in included studies (rounded to nearest 10 per 1000)
2 Serious limitations in design: none of the trials reported adequate methods for allocation concealment and masking of outcome
assessment.
3 In contrast to the other trials here Bowman 2000 aimed to compare azithromycin and tetracycline ‘ ‘ under practical operational
conditions - i.e. without supervision of the administration of the ointment’’. The results of this study were quite different from the other
trials and excluding it from the pooled estimated reduced the I2 value from 63% to 0% for 3 months follow-up and from 56% to 29% for
12 months follow-up.
4 Serious limitations in design: no trial reported adequate allocation concealment. Two out of the three trials reported masking outcome
assessment.
5 Very serious inconsistency: Effect estimates ranged from 0.57 in favour of oral antibiotics to 6.05 in favour of topical antibiotics,
although confidence intervals for all studies overlapped with each other. Only 8 events in total in the control groups of these three studies.
6 Serious limitations in design: no trial reported adequate allocation concealment. One out of the two trials reported masking outcome
assessment.
7 Very serious inconsistency: One trial found in favour of oral antibiotics with a RR of 0.5, the other found in favour of topical antibiotics
with a RR of 2.59. Neither trial was statistically significant and their confidence intervals overlapped.
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Oral azithromycin compared to control for trachoma
Patient or population: patients with trachoma
Settings: communities
Intervention: oral azithromycin
Comparison: control
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
control oral azithromycin
Active trachoma
Follow-up: 12 months
See comment See comment Not estimable 2764
(2 studies)
⊕⊕⊕©
moderate1,2
Best estimate of effect is
likely to come from TANA
2009 RR 0.58 (95% CI
from individual analysis
0.52 to 0.65, 95% CI ad-
justed for clustering 0.47
to 0.72).3
Ocular chlamydia tra-
chomatis infection
Follow-up: 12 months
Medium risk population4 RR 0.35
(0.21 to 0.60)5
4345
(4 studies)
⊕⊕⊕©
moderate1,6
100 per 1000 35 per 1000
(21 to 60)
High risk population4
500 per 1000 175 per 1000
(105 to 300)
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio;
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Trials were of variable quality but the majority of evidence was from TANA 2009 which was judged to be at low risk of bias so we did
not downgrade for limitations in design.
2 Serious inconsistency: TANA 2009 and Atik 2006 provided different estimates of effect. RR 0.58, (95% CI 0.67, 1.94) in TANA 2009
compared to RR 1.14, (0.67, 1.94) in Atik 2006.
3 TANA 2009 randomised 24 communities and was judged to be at low risk of bias. Atik 2006 randomised 2 communities and was
judged to be at a greater risk of bias. For that reason, we judge that the estimate of effect from TANA 2009 is likely to provide a better
estimate of the true effect.
4 Populations with medium (10%) prevalence and high (50%) prevalence of trachoma.
5 These confidence intervals do not take into account the cluster design of the study. Adjusting for cluster design of the study did not
affect the conclusions. Adjusting for an ICC of 0.2 gave a confidence interval for the pooled risk ratio of 0.20 to 0.63.
6 Serious inconsistency: Estimates of effect in the four studies range from 0.04 to 0.61.
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Oral azithromycin compared to topical tetracycline for trachoma
Patient or population: patients with trachoma
Settings: communities
Intervention: oral azithromycin
Comparison: topical tetracycline
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
topical tetracycline oral azithromycin
Active trachoma
Follow-up: 3 months
See comment See comment Not estimable 6002
(3 studies)
⊕⊕©©
low1,2
ACT 1999 Egypt: RR 0.52
(95% CI 0.43,0.64); ACT
1999 Tanzania RR 1.16 (1.
00,1.36); ACT 1999 The
Gambia RR 0.76 (0.50,1.
15)
Ocular C. trachomatis in-
fection
Follow-up: 3 months
See comment See comment Not estimable 5773
(3 studies)
⊕⊕©©
low1,2
ACT 1999 Egypt: RR 0.22
(95% CI 0.11,0.44); ACT
1999 Tanzania RR 0.68 (0.
49,0.95); ACT 1999 The
Gambia RR 0.51 (0.37,0.
70)
Active trachoma
Follow-up: 12 months
See comment See comment Not estimable 5414
(3 studies)
⊕⊕©©
low1,2
ACT 1999 Egypt: RR 0.74
(95% CI 0.61,0.90); ACT
1999 Tanzania RR 1.19 (1.
02,1.40); ACT 1999 The
Gambia RR 0.55 (0.40,0.
75)
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Ocular C. trachomatis in-
fection
Follow-up: 12 months
See comment See comment Not estimable 5276
(3 studies)
⊕⊕©©
low1,2
ACT 1999 Egypt: RR 0.48
(95% CI 0.31,0.74); ACT
1999 Tanzania RR 1.01 (0.
76,1.35); ACT 1999 The
Gambia RR 0.62 (0.44,0.
87)
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Serious limitations in design: Three cluster-randomised trials, two of the trials only randomised two communities to oral/topical
antibiotic. Assessment of trachoma was not masked but assessment of ocular infection was. Recruitment bias not addressed and
problems with incomplete outcome data. Some attempt made to adjust for baseline imbalances.
2 Serious inconsistency:
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D I S C U S S I O N
Summary of main results
Trials included in this review provide evidence that individuals
with trachoma benefit from antibiotic treatment (Summary of
findings for the main comparison). Antibiotic treatment reduces
the risk of active trachoma and ocular C. trachomatis infection up
to 12 months after treatment. The trials included in this review
were clinically and statistically heterogeneous and most had seri-
ous limitations in their design. This makes it difficult to estimate
the size of the effect; the current best guess would be an approx-
imate 20% risk reduction. Overall the quality of the evidence is
graded as low. Oral and topical treatments appeared to have simi-
lar effects if used as prescribed (Summary of findings 2). One trial
(Bowman 2000) compared oral antibiotic and unsupervised top-
ical treatment and found the oral antibiotic to be more effective
“under practical operational conditions”, which may have been
due to poor compliance with the more complex topical treatment
regimen.
Only three of the more recent trials in individuals used azithro-
mycin, which is the currently recommended oral antibiotic treat-
ment. None of these trials had a no treatment group. However,
in the individually-randomised trials there was no evidence that
azithromycin was less effective than topical tetracycline.
We identified four community-based trials comparing azithromy-
cin versus no treatment. These trials were of variable quality and
size, however there was one large, good quality trial conducted in
Ethiopia (TANA 2009) that provided good evidence that commu-
nity-based treatment with a single dose of azithromycin reduces
the prevalence of active trachoma and ocular chlamydial infection
in children up to 12 months after treatment (Summary of findings
3).
Only one trial compared oral versus topical community-based
treatment (Summary of findings 4). This study was conducted in
three countries in Africa and therefore is included as three separate
studies in this review. Data from this study were inconsistent. In
The Gambia and Egypt there was some evidence that oral azithro-
mycin was more effective than topical tetracycline, particularly
with regards to ocular infection. However, after adjustment for
the cluster design of the study these findings were not statistically
significant and were not replicated consistently in the Tanzanian
arm of the study.
None of the included trials reported any serious adverse events
associated with either of the currently used antibiotics, azithro-
mycin and topical tetracycline. However, for many of the trials it
was not clear whether data on adverse effects had been collected
systematically. In the one trial that did report these data, between
10% and 15% of people experienced symptoms such as nausea
and vomiting with azithromycin treatment.
Overall completeness and applicability of
evidence
A strength of the evidence is that the included trials come from
many different countries and populations. However, it is unfortu-
nate that heterogeneity between trial results means that we cannot
estimate with any confidence the size of the effect for treatment of
trachoma with oral or topical antibiotics, although it is likely that
both oral and topical treatments have a beneficial effect.
Almost all the trials in individuals were done in children and the
generaliseability of these findings to adults is uncertain. In the
community-based trials, data were reported for adults and chil-
dren. With the small number of trials it was not possible to de-
termine whether the effects are different in these groups but one
study (TANA 2009) provided data on ocular infection after mass
treatment in both children and adults. The observed risk ratio in
children was 0.32 (95% CI 0.26 to 0.40) and in adults was 0.49
(0.33 to 0.71).
Evidence for community-based or mass treatment campaigns is
sparse. It was not possible to determine who should be treated on
the basis of available data, what the important factors are in plan-
ning treatment strategies and whether it is the whole community,
all children under 10 years of age, all women and children or fam-
ilies of all children with active trachoma. There is some evidence
that frequent treatment of children may be an effective strategy to
reduce the community prevalence of infection (TANA 2009).
Azithromycin was given in the trials as a single, double or triple
dose but it was not possible to determine whether there was any
difference in effect. Where azithromycin is not donated, there is a
major cost difference between topical tetracycline and oral azithro-
mycin, but it was not possible to determine which is the more
cost-effective strategy per extra case cured. Some populations in
which trachoma is endemic are subject to migration and that may
account in part for the low follow-up rates in the community tri-
als; it may also have implications in determining themost effective
treatment in those populations where new infected cases migrate
into the community.
Our review does not directly address the evidence for the WHO
guidelines. In part this is because we did not identify any trial
data that directly tested the efficacy of the mass antibiotic admin-
istration schedules currently recommended. These are that where
the baseline district-level prevalence of TF in one to nine year-old
children is 10% or greater, mass antibiotic treatment should be
undertaken annually for three years before a repeat district-level
survey (Solomon 2006).
Quality of the evidence
The included trials were published from 1966 onwards and their
quality was variable. The quality of evidence for most outcomes
was low, particularly for the comparison antibiotics versus no treat-
ment (Summary of findings for the main comparison). Reporting
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of sequence generation and allocation concealment was not good
and it was often difficult to assess the effect of incomplete data due
to inadequate reporting. There was considerable heterogeneity of
results. However, masking of outcome assessment was reported
for laboratory analyses (less so for clinical assessments of active
trachoma) and there was little evidence of selective outcome re-
porting. There was moderate quality evidence for the comparison
of oral and topical antibiotics for the outcome active trachoma
(Summary of findings 2).
The community-based trials were also of poor methodological
quality with the exception of one study (TANA 2009) (Summary
of findings 3; Summary of findings 4). Themain problemwith the
included studies was that in most of the studies only two commu-
nities were randomly allocated to treatment (only two trials ran-
domised sufficient number of clusters). Although adjustment for
baseline characteristics can alleviate this problem to some extent,
the interpretation of these studies is always problematic as it is dif-
ficult to exclude the alternative explanation that there is some char-
acteristic that is different between the communities (apart from
treatment of trachoma) and which may be the real cause of any
observed differences in outcome. There was also little information
on other potential sources of bias in cluster-randomised trials such
as recruitment bias.
Three community-based trials (Chidambaram 2006; Lee 2007;
TANA 2009) had a ’delayed treatment’ design that involved ran-
domly selecting clusters for treatment and comparing the preva-
lence of trachoma 12months after treatment with a random selec-
tion of untreated clusters that are then enrolled in the treatment
programme. This study design overcomes the ethical dilemma of
surveying communities for trachoma and then withholding treat-
ment for 12 months but has the disadvantage that baseline data
on trachoma are not available in the control group.
Potential biases in the review process
This review has been substantially revised for the update. New
methods, such as assessment of risk of bias and subgroup and sen-
sitivity analyses, have been incorporated. A new protocol was not
written. It is possible that the update could have been influenced
by knowledge of the trial results.
Agreements and disagreements with other
studies or reviews
This update, like previous versions of the Cochrane review of an-
tibiotics for trachoma (Mabey 2002; Mabey 2005), found some
evidence of benefit of treatment of individuals with clinical signs
of active trachoma, but only limited evidence to support the use
of oral azithromycin in preference to topical tetracycline. In con-
trast to those previous Cochrane reviews, we found some good
quality evidence demonstrating the effectiveness of community-
based treatment, with some limited evidence of greater benefit of
mass treatment with azithromycin over mass treatment with top-
ical tetracycline.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Whilst the data are not of sufficient quality to make firm conclu-
sions, there is some evidence that people treated with either oral or
topical antibiotics may experience a reduction in the risk of active
trachoma (perhaps of the order of 20% relative risk reduction). It
is likely that oral azithromycin and topical tetracycline have simi-
lar effects if used as prescribed.
Community-based trials show that mass administration of antibi-
otics reduces the prevalence of active trachoma andocular infection
withC.trachomatis.There were no trial data that directly tested the
mass antibiotic administration schedules currently recommended
by WHO.
Implications for research
TheAlliance for theGlobal Elimination of Trachoma has endorsed
the donation of azithromycin for the treatment of trachoma. This
would be an ideal setting in which to conduct community-ran-
domised trials, under operational conditions, comparing the ef-
fect of mass distribution of azithromycin to that of placebo or
no treatment. Opportunities for ethically conducting such trials
occur in countries and districts newly enrolling in trachoma con-
trol programmes. Inequities are bound to exist in some settings at
start-up, when antibiotics and resources for their distribution are
generally in limited supply. Allocating interventions randomly in
these circumstances is reasonable, with roll-out of the intervention
to areas initially randomised to ’control’ in later treatment rounds.
Such an approach has been used in several of the trials included in
this review. Trials to determine optimal dosages and dosage inter-
vals of azithromycin at various levels of endemicity, test the most
appropriate thresholds for starting and stopping mass treatment,
and to determine which subgroups will need to be treated at var-
ious stages of the pathway towards elimination are also required;
where potential strategies to evaluate could be selected on the basis
of recent mathematical modelling work. Cost effectiveness per ex-
tra case cured should be one of the outcomemeasures. The adverse
effects of azithromycin and emergence of resistance are also areas
that should be addressed.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
ACT 1999 Egypt
Methods Allocation: random within one matched pair.
Unit of randomisation: village.
Masking:
participant - no,
provider - no,
outcome - no.
Exclusions after randomisation: no.
Losses to follow up: yes, temporary absence.
Participants Country: Egypt.
Number randomised: 2238.
Age (ave.): all ages.
Sex: not reported.
Clinical grading: Dawson 1981.
Lab tests: LCR.
Inclusion criteria: all villagers present.
Exclusion criteria: none, but alternative treatment for azithromycin-allocated women at
childbearing age
Interventions TREATMENT: azithromycin.
Administration: oral.
Dose: 20 mg/kg up to 1 g.
Duration: once a week for 3 weeks. Women of childbearing age erythromycin for 14
days, 500 mg twice daily or 250 mg four times daily (amoxicillin in case of intolerance)
COMPARISON: oxytetracycline.
Administration: topical.
Dose: 1%.
Duration: once daily for 6 weeks.
Outcomes Primary: active trachoma.
Secondary: infection.
Notes “Compliance was good for all groups, except the tetracycline treatment village in Egypt
(table 2).” (page 633). From table 2, the percentage receiving at least 1 dose of azithro-
mycin was 95% and the percentage receiving 28 applications of tetracycline was 59.5%
Only one pair of villages randomised.
Risk of bias
Bias Authors’ judgement Support for judgement
Blinding?
Active trachoma
High risk The treatments were quite different - oral
versus topical. No measures were reported
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ACT 1999 Egypt (Continued)
to mask study participants and personnel
from knowledge of which intervention a
participant received
Blinding?
Ocular Chlamydia trachomatis infection
Low risk “Laboratory staff were not aware of the clin-
ical and treatment status of study partici-
pants” and “Identification numbers for lab-
oratory samples differed from those used
on the ocular examination forms to conceal
village and treatment status from the labo-
ratory staff ” (page 632)
Incomplete outcome data addressed?
Active trachoma
High risk “Some individuals or families could not be
reached at scheduled treatment times (they
worked out of town, had moved away on
a temporary or permanent basis, or were
working in the fields when the teams were
present). There were some refusals at all
sites.” Egypt: ”little movement was docu-
mented“ (page 633)
From table 6 (page 633): 92% of azithro-
mycin group and86%of tetracycline group
had assessment of active trachoma at base-
line. At one year, 87% of azithromycin
group and 75% of tetracycline group had
data on active trachoma
Incomplete outcome data addressed?
Ocular Chlamydia trachomatis infection
High risk From table 4 (page 632): 81% of azithro-
mycin group and58%of tetracycline group
had assessment of ocular infection after
treatment. At one year, 80% of azithromy-
cin group and 69% of tetracycline group
had data on ocular infection
Free of selective reporting? Low risk Both outcomes of relevance to this review
reported.
Free of other bias? Low risk
Recruitment bias addressed? Unclear risk Recruitment bias was not specifically ad-
dressed in the report however the following
statement was made “At all study sites we
attempted to treat every individual present
in each village” (Schachter page 631)
The following data were available in the
report which suggests that recruitment bias
may have been a possibility
A=Azithromycin group T=
tetracycline group, numbers expressed as%
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ACT 1999 Egypt (Continued)
of pre-study census
Pre-study census: A: 1179 T: 1212
At time of treatment: A: 1139 (97%) T:
1099 (91%)
Baseline clinical trachoma status: A: 1080
(92%) T: 1044 (86%)
Compliance (at least 1 dose azithromycin
or 28 applications of tetracycline) A: 95%
T:60%
Baseline imbalances addressed? Low risk ”In each of the endemic areas, pairs of vil-
lages were matched on the basis of an ini-
tial rapid assessment of the trachoma rate
among children aged between 1 and 10
years. One member of each village pair was
randomly assigned mass treatment with
oral azithromycin, with the other receiv-
ing the topical tetracycline regimen; in each
village we generated a random number for
each and took the number closest to one to
be assigned azithromycin“. (Schachter page
631). However, note in Egypt only 2 clus-
ters were randomised
Baseline comparability of clusters not re-
ported in Schachter but “[...], we have done
multivariate analyses, which adjust for clus-
tering of individual within households and
for co-variates that may affect an individ-
uals’ risk of being infected with chlamydia
(LCR positive) at 1 year. The assumption
underlying these models is that after ad-
justment for covariates there are no village
characteristics, other than treatment type,
that affect the risk of positivity at 1 year
after treatment” (Schachter page 632)
ACT 1999 Tanzania
Methods Allocation: random within one matched pair.
Unit of randomisation: village.
Masking:
participant - no,
provider - no,
outcome - no.
Exclusions after randomisation: none
Losses to follow up: yes, temporary absence.
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ACT 1999 Tanzania (Continued)
Participants Country: Tanzania.
Number randomised: 3261.
Age (ave.): all ages.
Sex: not reported.
Clinical grading: Dawson 1981.
Lab tests: LCR.
Inclusion criteria: all villagers present.
Exclusion criteria: none, but alternative treatment for azithromycin-allocated women at
childbearing age
Interventions TREATMENT: azithromycin.
Administration: oral.
Dose: 20 mg/kg up to 1 g.
Duration: once a week for 3 weeks. Women of childbearing age erythromycin for 14
days, 500 mg twice daily or 250 mg four times daily (amoxicillin in case of intolerance)
COMPARISON: oxytetracycline.
Administration: topical.
Dose: 1%.
Duration: once daily for 6 weeks.
Outcomes Primary: active trachoma.
Secondary: infection.
Notes Only one pair of villages randomly allocated to treatment.
High population movement.
Risk of bias
Bias Authors’ judgement Support for judgement
Blinding?
Active trachoma
High risk The treatments were quite different - oral
versus topical. No measures were reported
to mask study participants and personnel
from knowledge of which intervention a
participant received
Blinding?
Ocular Chlamydia trachomatis infection
Low risk “Laboratory staff were not aware of the clin-
ical and treatment status of study partici-
pants” and “Identification numbers for lab-
oratory samples differed from those used
on the ocular examination forms to conceal
village and treatment status from the labo-
ratory staff ” (page 632)
Incomplete outcome data addressed?
Active trachoma
High risk Some individuals or families could not be
reached at scheduled treatment times (they
worked out of town, had moved away on
a temporary or permanent basis, or were
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ACT 1999 Tanzania (Continued)
working in the fields when the teams were
present). There were some refusals at all
sites (page 633)
From table 6 ( page 633): 78% of azithro-
mycin group and88%of tetracycline group
had assessment of active trachoma at base-
line. At one year, 60% of azithromycin
group and 77% of tetracycline group had
data on active trachoma
Incomplete outcome data addressed?
Ocular Chlamydia trachomatis infection
High risk From table 4 ( page 632): 58% of azithro-
mycin group and78%of tetracycline group
had assessment of ocular infection after
treatment. At one year, 45% of azithromy-
cin group and 61% of tetracycline group
had data on ocular infection
Free of selective reporting? Low risk Both outcomes of relevance to this review
reported.
Free of other bias? Low risk
Recruitment bias addressed? Unclear risk Recruitment bias was not specifically ad-
dressed in the report however the following
statement was made “At all study sites we
attempted to treat every individual present
in each village” (Schachter page 631)
The following data were available in the
report which suggests that recruitment bias
may have been a possibility
A=Azithromycin group T=
tetracycline group, numbers expressed as%
of pre-study census
Pre-study census: A: 2167 T: 1179
At time of treatment: A: 2161 (100%) T:
1100 (93%)
Baseline clinical trachoma status: A: 1696
(78%) T: 1036 (88%)
Compliance (at least 1 dose azithromycin
or 28 applications of tetracycline) A: 89%
T: 90%
Baseline imbalances addressed? Low risk Baseline comparability of clusters not re-
ported in Schachter but “[...], we have done
multivariate analyses, which adjust for clus-
tering of individual within households and
for co-variates that may affect an individ-
uals’ risk of being infected with chlamydia
(LCR positive) at 1 year. The assumption
underlying these models is that after ad-
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justment for covariates there are no village
characteristics, other than treatment type,
that affect the risk of positivity at 1 year
after treatment.” (Schachter page 632)
ACT 1999 The Gambia
Methods Allocation: random within four matched pairs.
Unit of randomisation: village.
Masking:
participant - no,
provider - no,
outcome - no.
Exclusions after randomisation: no.
Losses to follow up: yes, temporary absence.
Participants Country: The Gambia.
Number randomised: 1753.
Age (ave.): all ages.
Sex: not reported.
Clinical grading: Dawson 1981.
Lab tests: LCR.
Inclusion criteria: all villagers present.
Exclusion criteria: none, but alternative treatment for azithromycin-allocated women at
childbearing age
Interventions TREATMENT: azithromycin.
Administration: oral.
Dose: 20 mg/kg up to 1 g.
Duration: once a week for 3 weeks. Women of childbearing age erythromycin for 14
days, 500 mg twice daily or 250 mg four times daily (amoxicillin in case of intolerance)
COMPARISON: oxytetracycline.
Administration: topical.
Dose: 1%.
Duration: once daily for 6 weeks.
Outcomes Primary: active trachoma.
Secondary: infection.
Notes Very high migration rate.
Risk of bias
Bias Authors’ judgement Support for judgement
Blinding?
Active trachoma
High risk The treatments were quite different - oral
versus topical. No measures were reported
to mask study participants and personnel
34Antibiotics for trachoma (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
ACT 1999 The Gambia (Continued)
from knowledge of which intervention a
participant received
Blinding?
Ocular Chlamydia trachomatis infection
Low risk “Laboratory staff were not aware of the clin-
ical and treatment status of study partici-
pants” and “Identification numbers for lab-
oratory samples differed from those used
on the ocular examination forms to conceal
village and treatment status from the labo-
ratory staff ” (Schachter page 632)
Incomplete outcome data addressed?
Active trachoma
High risk All clusters completed the trial in theory
although one cluster allocated to azithro-
mycin had very poor follow-up (0% at 12
months).
Some individuals or families could not be
reached at scheduled treatment times (they
worked out of town, had moved away on
a temporary or permanent basis, or were
working in the fields when the teams were
present). There were some refusals at all
sites (Schachter page 633)
From table 6 (Schachter page 633): 91%
of azithromycin group and 82% of tetra-
cycline group had assessment of active tra-
choma at baseline. At one year, 65% of
azithromycin group and 50% of tetracy-
cline group had data on active trachoma
Incomplete outcome data addressed?
Ocular Chlamydia trachomatis infection
High risk From table 4 (Schachter page 632): 61%
of azithromycin group and 54% of tetra-
cycline group had assessment of ocular in-
fection after treatment. At one year, 47%
of azithromycin group and 36% of tetracy-
cline group had data on ocular infection
Fraser-Hurt: Individual factors statistically
associated with attendance at none or only
one of the three post-treatment surveys
were increasing age (P = 0.02), Wolof eth-
nicity (P < 0.001), absence of active tra-
choma at baseline (P = 0.001), and non-
compliance with treatment (P = 0.06)
Free of selective reporting? Low risk Both outcomes of relevance to this review
reported.
Free of other bias? Low risk
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Recruitment bias addressed? Unclear risk “All residents who were present at the pre-
treatment survey were eligible for partici-
pation in the trial.” (Fraser-Hurt)
“At all study sites we attempted to treat
every individual present in each village”
(Schachter page 631)
Baseline imbalances addressed? Low risk “In each of the endemic areas, pairs of vil-
lages were matched on the basis of an ini-
tial rapid assessment of the trachoma rate
among children aged between 1 and 10
years. One member of each village pair was
randomly assigned mass treatment with
oral azithromycin, with the other receiv-
ing the topical tetracycline regimen; in each
village we generated a random number for
each and took the number closest to one to
be assigned azithromycin” (Schachter page
631).
“The villages were matched in pairs of sim-
ilar size, and azithromycin and tetracycline
were allocated randomly within these pairs.
” (Fraser-Hurt page 633). Baseline com-
parability of clusters reported (Fraser-Hurt
table 1 page 635). There were some base-
line imbalances but these were controlled
for in the analysis: “Point estimates of the
odds ratio for the comparison of azithro-
mycin with tetracycline, adjusted for age,
latrine ownership and, where appropriate,
trachoma status at baseline, were obtained
using logistic regression with individual
records.” (Fraser-Hurt page 634)
Baseline comparability of clusters not re-
ported in Schachter but “[...], we have done
multivariate analyses, which adjust for clus-
tering of individual within households and
for co-variates that may affect an individ-
uals’ risk of being infected with chlamydia
(LCR positive) at 1 year. The assumption
underlying these models is that after ad-
justment for covariates there are no village
characteristics, other than treatment type,
that affect the risk of positivity at 1 year
after treatment.” (Schachter page 632)
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Methods Allocation: random allocation of surgery or surgery plus antibiotics
Unit of randomisation: commune.
Masking:
participant - no,
provider - no,
outcome - unclear.
Exclusions after randomisation: no.
Losses to follow up: unclear.
Participants Country: Vietnam.
Number randomised: 2 communes randomised; 1851 people enrolled in the study
Age: 6 months and older.
Sex: approximately 60% female.
Clinical grading: Thylefors 1987.
Lab tests:Amplicor-PCR (polymerase chain reaction) assay (Roche Diagnostics, Branch-
burg, NJ) of conjunctival samples
Inclusion criteria: all ages 6 months and older.
Exclusion criteria: none, but pregnant women received erythromycin
Interventions Azithromycin 20 mg/kg for children; 1 g for adults. Pregnant women received ery-
thromycin
All commune residents older than 6 months were included in the study. There were 2
components to the assessment and intervention. The first component involved exami-
nation of all schoolchildren aged 5 through 15 years; children who had active trachoma
defined as follicular inflammation, intense inflammation, or both were considered index
cases. The second component included examination of the remaining individuals either
at a central commune or village site
Index cases and their household members were treated with a single oral dose of azithro-
mycin at baseline and 12 months. Non-index cases and non-household members who
had active trachoma (follicular inflammation, intense inflammation, or both) received
topical tetracycline
In the control community trachomatous trichiasis cases were identified and informed of
the availability of surgery. All patients who had active trachoma (follicular inflammation,
intense inflammation, or both) received topical tetracycline
Outcomes Active trachoma and C. trachomatis infection.
Notes Only two communes compared.
Risk of bias
Bias Authors’ judgement Support for judgement
Blinding?
Active trachoma
Unclear risk The interventions were not masked but
the communes were “geographically iso-
lated from one another” (page 1489). It
was not clear if the participants were aware
of the existence of other potential interven-
tions
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“At each time point of the study, all partic-
ipants were examined by an ophthalmolo-
gist and graded for trachoma in a masked
fashion using a modified grading scale”
(page 1489)
However, the extent to which the ophthal-
mologist might be aware of what treatment
the community had received was not dis-
cussed
Blinding?
Ocular Chlamydia trachomatis infection
Low risk “Samples were labelled with date and a
unique identification number to maintain
confidentiality and to process samples in a
masked fashion” (page 1489)
Incomplete outcome data addressed?
Active trachoma
High risk Both clusters completed the trial. Response
rates were not reported explicitly
The following gives the total population
and the percentage graded for trachoma
at baseline, 6 months, 12 months and 24
months (from table 1 and figure 2)
Azithromycin community: total = 659:
100%; 86%;79%;56%.
Untreated community: total=1192; 100%;
89%; 83%; 72%.
Incomplete outcome data addressed?
Ocular Chlamydia trachomatis infection
High risk The following gives the total population
and the percentage graded for ocular infec-
tion at baseline, 6 months, 12 months and
24 months (from table 1 and figure 2)
Azithromycin community: total = 659:
98%;79%;100%;52%.
Untreated community: total=1192; 95%;
76%; 100%; 71%.
A response rate of 100% at one year is un-
usual and might suggest that some of the
people assessed at one year were not present
at census. it is also surprising that both
communities had 100% follow-up at the
same time point
Free of selective reporting? Low risk Both outcomes of relevance to this review
reported.
Free of other bias? Low risk
Recruitment bias addressed? Unclear risk “selected communes were geographically
isolated from one another” (page 1489)
and “All commune residents older than 6
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months were included in the study” (page
1489) however no information on response
rates were given so it is not clear how many
of the residents actually took part in the
study
Baseline imbalances addressed? High risk Only two clusters included in the trial so
no pair-matching. Baseline comparability
of clusters was reported with respect to sex
and trachoma only (table 1 page 1491).
There was a higher baseline prevalence of
active trachoma in people aged > 15 in the
control cluster (10.6% versus 3.6% P < 0.
001) and higher baseline prevalence of ac-
tive trachoma in children 5-15 years in the
intervention cluster (9.2% versus 4.7% P
= 0.033). Statistical adjustment was made
for sex, age, and having at least one person
with chlamydial infection in the household
Attiah 1973
Methods Allocation: stratified random.
Unit of randomisation: individual.
Masking:
participant - no,
provider - yes,
outcome - yes.
Exclusions after randomisation: no.
Losses to follow-up: 0.
Unusual study design: follow up right after treatment termination, over two weeks
Participants Country: Egypt
Number randomised: 228.
Age (ave.): 6 to 12 years.
Sex: not reported.
Clinical grading: WHO.
Lab tests: none.
Inclusion criteria: active trachoma or ’undetermined case’.
Exclusion criteria: none.
Interventions TREATMENT 1: tetracycline derivative GS2989.
Administration: topical.
Dose: 0.25%.
duration: once every school day for 11 weeks.
TREATMENT 2: terramycin.
Administration: topical.
Dose: not reported.
Duration: once every school day for 11 weeks.
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COMPARISON: no treatment.
Administration: not applicable.
Dose: not applicable.
Duration: not applicable.
Outcomes Primary: active trachoma.
Secondary: -
Adverse effects: n.a.
Notes Treatment irregular, although intended for every school day.
One village - no description of why it was chosen. Only school children. 228 subjects
divided into 11 clinical groups, each of which randomised into three intervention groups.
Unclear why 10 weeks and 6 days was felt to be the optimal duration of therapy
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment? Unclear risk Not reported
Blinding?
Active trachoma
Unclear risk “the principle of double blindness ensured
in the experiment” (page 11)
“The examiner had no knowledge of the
treatment assignment to the groups or of
the randomisation process used in the trial”
(page 12)
“After three months treatment, the results
were checked using WHO criteria without
investigators knowing what treatment ap-
plied” (page 16)
However, the report gave no indication
as to how the groups were masked and
whether the control group received any
placebo treatment
Incomplete outcome data addressed?
Active trachoma
Unclear risk Reported 100% follow up. This is unusual
and could indicate that children who were
not followed-up were not reported. How-
ever, 100%may be feasible in a school situ-
ation.We have left this as “unclear” because
we cannot tell which of the two options ap-
ply
Incomplete outcome data addressed?
Ocular Chlamydia trachomatis infection
Unclear risk No data on ocular infection reported.
Free of selective reporting? Low risk Clinical examination only and no sugges-
tion that any assessment of ocular infection
made
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Free of other bias? Low risk
Bailey 1993
Methods Allocation: not reported.
Unit of randomisation: unclear “randomisation was by room, all active cases within a
room receiving the same treatment” (page 454)
Masking:
participant - no,
provider - no,
outcome - unclear.
Exclusions after randomisation: none.
Losses to follow up: none.
Participants Country: The Gambia.
Number randomised: 194.
Age: 9 months to 60 years.
Sex: 51% male.
Clinical grading: Dawson 1981.
Lab tests: IDEIA amplified enzyme-linked immunosorbent assay (Dako) for genus-
specific lypopolysaccharide antigen
Inclusion criteria: active trachoma.
Exclusion criteria: pregnant or lactating.
Interventions Oral azithromycin single-dose 20 mg/kg.
Topical tetracycline 1% eye ointment twice daily for six weeks. Those with ’severe disease’
also received oral erythromycin stearate 250 mg four times daily for two weeks
Outcomes “resolution of disease”.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment? Unclear risk No information on how the sequence was
generated or allocated “Randomisationwas
by room, all active cases within a room re-
ceiving the same treatment” (page 454)
Blinding?
Active trachoma
Unclear risk No placebos used for either tablets or oint-
ment. “Subjects were examined [...] by a
trained observer (RLB) unaware of treat-
ment allocation” (page 454)
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Blinding?
Ocular Chlamydia trachomatis infection
Unclear risk No specific information on this but as clin-
ical examinations masked it is likely that
the laboratory analyses were as well
Incomplete outcome data addressed?
Active trachoma
Low risk Of 194 subjects randomised, 194 examined
at 4 weeks, 194 examined at 8 weeks, 191
examined at 16 weeks, and 193 examined
at 26 weeks (one subject had died by that
point)
Incomplete outcome data addressed?
Ocular Chlamydia trachomatis infection
Low risk Of 194 subjects randomised, 194 examined
at 4 weeks, 194 examined at 8 weeks, 191
examined at 16 weeks, and 193 examined
at 26 weeks (one subject had died by that
point)
Free of selective reporting? Low risk Both outcomes - infection and clinical dis-
ease - reported
Free of other bias? Low risk
Bowman 2000
Methods Allocation: randomisation by block.
Unit of randomisation: individual.
Masking:
participant - no,
provider - no,
outcome - yes.
Exclusions after randomisation: no.
Losses to follow up: numbers recorded.
Participants Country: The Gambia.
Number randomised: 314.
Age: 6 months to 10 years.
Sex: Boys 50%.
Clinical grading: simplified WHO scale 1987.
No lab tests.
Interventions TREATMENT: single-dose azithromycin 20 mg/kg.
COMPARISON: topical tetracycline applied once by a nurse in front of the care-giver
and then twice daily by care-giver for 6 weeks
Outcomes Primary: active trachoma.
No secondary outcome.
Notes Trial aim to compare treatments under operational and not best possible conditions
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Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment? Low risk “Codes in numbered sealed envelopes were
used by the nurse administering treatment
to allocate treatment to the subject. The
clinical assessors had no knowledge of the
randomisation sequence or of the treat-
ment received by previous subjects. Sim-
ilarly the nurse had no knowledge of the
block randomisation procedure and did
not examine the children but administered
treatment according to the allocation in the
envelope.” (page 4075).
Blinding?
Active trachoma
Low risk Interventions were different - oral dose of
azithromycin syrup versus topical tetracy-
cline -so not possible to prevent knowledge
to caregivers and participants. However,
eyeswere gradedby “a clinical assessor blind
to the treatment allocation.” (page 4075).
“Patients were aware of their treatments,
and therefore inadvertent unmasking of the
clinical assessors at follow-up by the pa-
tients was possible. There were no reports
of the occurring, however, and the similar
cure rate ratios for both clinical and pho-
tographic outcome suggest that unmasking
and bias were not a significant problem.“
(page 4077)
Incomplete outcome data addressed?
Active trachoma
Low risk Figure 1 (page 4076).
Analysis was not by intention to treat as
4 participants received the wrong alloca-
tion and were analysed according to their
received treatment not according to their
random allocation. However as this num-
ber was low it is unlikely to have biased the
outcome
Of 154 children who received tetracycline
15 (10%) were not followed at 6 months;
of 160 who received azithromycin 11 (7%)
missed follow up. No reason was given for
loss to follow up but as this was low and not
substantially different between the groups
it is unlikely to have caused bias
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Incomplete outcome data addressed?
Ocular Chlamydia trachomatis infection
Unclear risk Not enough information provided
Free of selective reporting? Low risk This study reported one of the primary out-
comes for this review - active trachoma.
There was no indication that the other out-
comeC. trachomatis infection was collected
but not reported.
Free of other bias? Low risk
Chidambaram 2006
Methods Longitudinal cohort study conductedMarch 2003 toMarch 2005 in theGurage Zone of
Ethiopia. Eight randomly selected villages were assessed for ocular chlamydial infection.
Twelvemonths after treatment, an additional 2 untreated villages were randomly selected
from each of the original 8 peasant associations
Participants All residents aged 1 year or older.
Interventions Single-dose oral azithromycin (1 g in adults/20 mg/kg in children) directly observed
treatment. Pregnant
women, children younger than 1 year, and those allergic to macrolides were offered a 6-
week course of topical 1% tetracycline ointment (applied twice daily to both eyes, not
directly observed)
Outcomes Presence of ocular chlamydial infection in children aged 1 to 5. A random sample of
adults were tested at 18 months
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Blinding?
Active trachoma
High risk Unclear whether this outcome was col-
lected.
Blinding?
Ocular Chlamydia trachomatis infection
Unclear risk Masking not reported.
Incomplete outcome data addressed?
Active trachoma
Unclear risk Not applicable - prevalence surveys in se-
lected communities at 12 months
Incomplete outcome data addressed?
Ocular Chlamydia trachomatis infection
Unclear risk Not applicable - prevalence surveys in se-
lected communities at 12 months
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Free of selective reporting? Unclear risk Only ocular infection reported - data on
active trachoma were collected but not re-
ported
Free of other bias? Low risk
Recruitment bias addressed? Unclear risk No information on recruitment bias in the
report.
Baseline imbalances addressed? Unclear risk Difficult to assess as no data reported and
study design is such that information on
baseline infection status in control villages
not available
Cochereau 2007
Methods Allocation: randomisation by block.
Unit of randomisation: individual.
Masking:
participant - yes,
provider - yes,
outcome - yes.
Exclusions after randomisation: yes.
Losses to follow up: numbers recorded
Participants Country: Guinea-Conakry (comunity) and Pakistan (boys schools only)
Number randomised: 670
Age: 1-10 years.
Sex: 49.8% male
Clinical grading: simplified WHO scale 1987.
No lab tests.
Interventions Azithromycin 1.5% eye drops 2x daily for 2 days (n=224) and 2x daily for 3 days (n=
225) compared to oral azithromycin 20 mg/kg single dose (n=221)
Outcomes % clinical cure in children with clinically active trachoma 2 months after treatment
Notes In Pakistan only children from boys schools recruited.
Last observation carried forward for missing data.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment? Unclear risk “The randomisation list used random per-
muted blocks of six (SAS v 8.2). Within
each village, patient numbers were allo-
cated in ascending order using the next
45Antibiotics for trachoma (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Cochereau 2007 (Continued)
available number. Study drugs were identi-
fied by patient number using the randomi-
sation list. (Randomisation procedures and
treatments p668).
Blinding?
Active trachoma
Low risk “We used a double-dummy design with
placebo eye drops and placebo paediatric
suspension” (Randomisation procedures and
treatments p668).
Incomplete outcome data addressed?
Active trachoma
Low risk Follow-up data reported as follows (figure
1, page 669). Some patients may havemore
than one reason for not being followed up
2-day eye drops group (n=224):
· Did not receive allocated treatment
(lost to follow-up) (1)
· moved to another region (2)
· probably did not fit inclusion criteria
(22)
· use of other medications (1)
· non-compliance (2)
· no follow-up at 2 months (1)
· number available for analysis (199,
88.8%)
3-day eye drops group (n=225):
· moved to another region (9)
· probably did not fit inclusion criteria
(23)
· use of other medications (1)
· non-compliance (1)
· no follow-up at 2 months (7)
· patient request (1)
· adverse event (1)
· family member illness (1)
· number available for analysis (190,
84.4%)
Oral azithromycin (n=221)
· moved to another region (9)
· probably did not fit inclusion criteria
(33)
· non-compliance (2)
· no follow-up at 2 months (4)
· patient request (1)
· adverse event (1)
· family member illness (1)
· number available for analysis (179,
81.0%)
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Free of selective reporting? High risk “A conjunctival swabbing was taken on
days 0, 30 and 60 under strictly sterile con-
ditions and analyzed for Chlamydia tra-
chomatis using a polymerase chain reaction.
” Study assessments p668. The PCR used
(name of product used if a commercial as-
say, or details of method if an in-house
assay) are not specified, and no data on
PCR positivity are provided, other than the
statement “Positivity to Chlamydiawas not
confirmed to be a prognostic factor by the
stepwise logistic regression analysis.” (First
paragraph, page 669).
Free of other bias? High risk “In order to limit the confounding fac-
tors for assessing the outcome of the initial
trachoma episode, reinfection risks were
strictly controlled. Person coming to the
investigation centre with the affected chil-
dren were to be treated with oral azithrom-
cin. Soap was provided and villagers were
informed about well-known environmen-
tal risk factors for trachoma” (Randomisa-
tion procedures and treatments p668).
However, no information was provided on
the numbers of people offered and accept-
ing this treatment and the potential efficacy
of this additional intervention. Any imbal-
ance between the two groups in the extent
to which this was taken up
Darougar 1980
Methods Allocation: randomisation schedule, stratification by age, sex, trachoma intensity, dis-
eased children in family.
Unit of randomisation: individual.
Masking:
participant - no,
provider - no,
outcome: unclear.
Exclusions after randomisation: yes, poor compliers.
Losses to follow up: not given by group.
Unusual study design: family-based treatment (familymembers treated but not analysed)
Participants Country: Iran.
Number randomised: 147.
Age (ave.): pre-school (5.5 years).
Sex: 38% male.
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Clinical grading: Darougar 1980, 1981.
Lab tests: culture (Darougar 1970).
Inclusion criteria: active trachoma, residence in study village.
Exclusion criteria: none
Interventions TREATMENT 1: oxytetracycline.
Administration: topical.
Dose: 1%.
Duration: twice daily for 7 consecutive days every month for 12 months
TREATMENT 2: doxycycline.
Administration: oral.
Dose: 5 mg/kg.
Duration: one dose per month for 12 months.
COMPARISON: vitamin pills
Administration: oral.
Dose: not reported.
Duration: 1 dose per month for 12 months.
Outcomes Primary: active trachoma.
Secondary: culture (McCoy cells).
Adverse effects: n.a.
Notes Some data only in graphical form. Data on whole conjunctiva and upper conjunctiva
given. Patients with “active trachoma in their whole conjunctiva” were included. Patients
with active disease may have been excluded
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment? Unclear risk No information about allocation conceal-
ment although the study is described as
“double-blind” (abstract page 291)
Blinding?
Active trachoma
Unclear risk No information about the masking al-
though study is described as “double blind”
(see above). Treatments are different - top-
ical versus oral antibiotics versus vitamin
tablets - so the participants will not have
been masked.
Blinding?
Ocular Chlamydia trachomatis infection
Unclear risk See above.
Incomplete outcome data addressed?
Active trachoma
High risk 147 patients included; 18 excluded because
of inadequate treatment or follow-up; it
was not reported to which groups these 18
patients were originally allocated
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Incomplete outcome data addressed?
Ocular Chlamydia trachomatis infection
High risk See above.
Free of selective reporting? Low risk Both outcomes of relevance to this review
reported.
Free of other bias? Low risk
Dawson 1969 Sherman
Methods Allocation: random.
Unit of randomisation: individual.
Masking:
participant: yes,
provider: yes,
outcome: yes.
Exclusions after randomisation: no.
Losses to follow up: -
Unusual study design: two similar studies with few participants each
Participants Country: USA.
Number randomised: 29.
Age (ave.): 12 to 21 years.
Sex: not reported.
Clinical grading: MacCallan 1936
Lab tests: IFAT on conjunctival smears.
Inclusion criteria: active disease, boarding at Sherman Institute.
Exclusion criteria: none
Interventions TREATMENT: trisulphapyrimidines.
Administration: oral.
Dose: 3 daily doses to total 3.5 g/day
Duration: 21 consecutive days
COMPARISON: lactose-placebo.
Administration: oral.
Dose: not reported.
Duration: 3 daily for 3 consecutive weeks.
Outcomes Primary: active trachoma.
Secondary: positive IFAT (1 - 5 identifiable inclusions per 100 - 1000 cells)
Notes Participants from Indian reservations.
Numbers need to be read from figures, some not very clear.
Risk of bias
Bias Authors’ judgement Support for judgement
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Allocation concealment? Unclear risk ”At each school, a full-time nurse person-
ally administered all drugs and placebos.
All materials were coded, and the identify
of drug or placebo remained unknown to
subjects, nurse, and physicians throughout
the trials until all examination results had
been recorded” (page 582). This statement
suggests that allocationwas concealed how-
ever it does not tell us who allocated the
treatment
Blinding?
Active trachoma
Low risk “At each school, a full-time nurse person-
ally administered all drugs and placebos.
All materials were coded, and the identify
of drug or placebo remained unknown to
subjects, nurse, and physicians throughout
the trials until all examination results had
been recorded” (page 582)
Blinding?
Ocular Chlamydia trachomatis infection
Low risk The statement above implies that all out-
come assessments were masked including
laboratory analyses
Incomplete outcome data addressed?
Active trachoma
Unclear risk 36 children took part in one school, 29
in the other. All (100%) were followed
up. Theoretically they could have recruited
more and had some lost to follow-up which
they did not report but it is also possible
that in a boarding school environment loss
to follow-up would be nil. As we cannot
distinguish between these two possibilities
we have put unclear
Incomplete outcome data addressed?
Ocular Chlamydia trachomatis infection
Unclear risk See above
Free of selective reporting? Low risk Both outcomes of relevance to this review
reported.
Free of other bias? Low risk
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Methods Allocation: random.
Unit of randomisation: individual.
Masking:
participant - yes,
provider - yes,
outcome - yes.
Exclusions after randomisation: no
Losses to follow up: -
Unusual study design: two similar studies with few participants each
Participants Country: USA.
Number randomised: 36.
Age (ave.): 12 to 21 years.
Sex: not reported.
Clinical grading: Dawson 1966.
Lab tests: IFAT on conjunctival smears.
Inclusion criteria: active disease, boarding at Stewart School.
Exclusion criteria: none.
Interventions TREATMENT: trisulphapyrimidines.
Administration: oral.
Dose: 3.5 g/day.
Duration: 3 daily during 3 consecutive weeks.
COMPARISON: lactose-placebo.
Administration: oral.
Dose: not reported.
Duration: 3 daily for 3 consecutive weeks.
Outcomes Primary: active trachoma.
Secondary: positive IFAT (1 - 5 identifiable inclusions per 100 - 1000 cells)
Notes Participants from Indian reservations.
Numbers need to be read from figures, some not very clear.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment? Unclear risk ”At each school, a full-time nurse person-
ally administered all drugs and placebos.
All materials were coded, and the identify
of drug or placebo remained unknown to
subjects, nurse, and physicians throughout
the trials until all examination results had
been recorded” (page 582). This statement
suggests that allocationwas concealed how-
ever it does not tell us who allocated the
treatment
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Blinding?
Active trachoma
Low risk “At each school, a full-time nurse person-
ally administered all drugs and placebos.
All materials were coded, and the identify
of drug or placebo remained unknown to
subjects, nurse, and physicians throughout
the trials until all examination results had
been recorded” (page 582)
Blinding?
Ocular Chlamydia trachomatis infection
Low risk The statement above implies that all out-
come assessments were masked including
laboratory analyses
Incomplete outcome data addressed?
Active trachoma
Unclear risk 36 children took part in one school, 29
in the other. All (100%) were followed
up. Theoretically they could have recruited
more and had some lost to follow up which
they did not report but it is also possible
that in a boarding school environment loss
to follow up would be nil. As we cannot
distinguish between these two possibilities
we have put unclear
Incomplete outcome data addressed?
Ocular Chlamydia trachomatis infection
Unclear risk See above.
Free of selective reporting? Low risk Both outcomes of relevance to this review
reported.
Free of other bias? Low risk
Dawson 1997
Methods Allocation: random.
Unit of randomisation: blocks of eight.
Masking:
participant: for azithromycin,
provider: no,
outcome: yes.
Exclusions after randomisation: no.
Losses to follow up: absence in village/not found.
Unusual study design: oral placebo for different azithromycin regimens, no placebo for
topical treatment
Participants Country: Egypt.
Number randomised: 168.
Age (ave.): 2 to 10 years (4).
Sex: 59.5% male.
Clinical grading: Thylefors 1987.
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Lab tests: Thylefors 1987; Dawson 1981.
Inclusion criteria: active trachoma, two to 10 years, resident in a study village.
Exclusion criteria: missing baseline record.
Interventions TREATMENT: azithromycin.
Administration: oral.
Dose: 20 mg/kg
Duration: single dose; or single dose weekly for 3 weeks; or single dose monthly for six
months
COMPARISON: Oxytetracycline/polymyxin + oral placebo.
Administration: topical.
Dose: oxytetracycline 1%/polymyxin 10,000 units/g.
Duration: once daily for 5 consecutive days every 28 days for 6 times
Outcomes Primary: active trachoma.
Secondary: elementary bodies ≤ 200 or > 200 on conjunctival smears.
Adverse effects: -
Notes Epidemic of purulent conjunctivitis at 8/12 years; cut-off for positivity not justified.
Three azithromycin regimens analysed together.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment? Unclear risk ”This clinical trial was double-
masked, placebo-controlled, and random-
ized” (page 364). However, no information
about allocation concealment given. Treat-
ment groups were different, for example,
no ointment placebo and different dosing
schedules for oral antibiotic
Blinding?
Active trachoma
Unclear risk “Ophthalmologists experienced in the di-
agnosis of trachoma performed all exami-
nations and were masked as to the treat-
ment used” (page 365). However, no de-
tails of the masking were given and theo-
retically, as the treatments were different,
the examiners could have been unmasked
by their patients
Blinding?
Ocular Chlamydia trachomatis infection
Low risk Assessment of conjunctival specimens will
have been easier to mask
Incomplete outcome data addressed?
Active trachoma
Low risk Follow-up rates at 12 months were good
from 91% to 98%. Ointment group 42/
43, one oral dose 39/40, 3 oral doses 39/43,
6 oral doses 39/42. The groups with larger
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number of oral doses had lower follow-up
rates but these were only 4 and 3 children
respectively
“Inmost cases, children were lost to follow-
up at specific examinations because they
and their family were not in the village or
because the child could not be found on
the day of the examination.” (page 365).
Incomplete outcome data addressed?
Ocular Chlamydia trachomatis infection
Low risk See above.
Free of selective reporting? Low risk Both outcomes of relevance to this review
reported.
Free of other bias? Low risk
Foster 1966
Methods Allocation: random.
Unit of randomisation: individuals.
Masking:
participant: no,
provider: no,
outcome: yes.
Exclusions after randomisation: not reported.
Losses to follow-up: yes.
Participants Country: USA.
Number randomised: approx. 305.
Age (ave.): 8 to 20 years.
Sex: not reported.
Clinical grading: Thygeson 1960.
Lab tests: -
Inclusion criteria: active trachoma, studying in a study school.
Exclusion criteria: none.
Interventions TREATMENT 1: sulphamethoxypyridazine.
Administration: oral.
Dose: 0.5 g.
Duration: once daily for 5 consecutive days every week for 3 weeks
TREATMENT 2: tetracycline.
Administration: topical.
Dose: 1%.
Duration: 3 times daily on 5 consecutive days every week for 6 weeks
COMPARISON: no treatment.
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Outcomes Primary: active trachoma.
Secondary: none.
Adverse effects: not recorded.
Notes Participants boarding.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment? Unclear risk Not reported.
Blinding?
Active trachoma
Unclear risk The treatments were different so the stu-
dents will have known which treatment
they received (oral versus topical antibiotic)
Clinical outcome: “The examiner had no
knowledge of the earlier findings or of the
nature of the treatment of the students be-
ing examined, and the order of the exami-
nations was randomised” (page 452).
Potential for the examiners being told by
students which treatment they received
Incomplete outcome data addressed?
Active trachoma
High risk A total of 457 active cases were identified
but only results reported for 325 (71%)
“For the purpose of analysis, only the 325
students who were examined on all three
occasions are included in Tables 3,4 and 5.
” (page 452 and 453)
Incomplete outcome data addressed?
Ocular Chlamydia trachomatis infection
Unclear risk No data on ocular infection reported.
Free of selective reporting? Low risk Only clinical outcomes recorded but no in-
dication of any assessment of ocular infec-
tion
Free of other bias? Low risk
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Methods Allocation: random.
Unit of randomisation: individual.
Masking:
participant - yes,
provider - yes,
outcome - yes.
Exclusions after randomisation: no.
Losses to follow up: poor compliance, lack of sample.
Participants Country: USA.
Number randomised: 120.
Age (ave.): 7 to 13 years (9.9).
Sex: not reported.
Clinical grading: Dawson 1969.
Lab tests: IFAT on scrapings of upper tarsal conjunctival epithelium
Inclusion criteria: active disease, boarding at study school.
Exclusion criteria: none
Interventions TREATMENT: doxycycline.
Administration: oral.
Dose: 2.5-4.0 mg/kg.
Duration: once daily for 5 consecutive days every week up to 28 doses in 40 days
COMPARISON: placebo.
Administration: oral.
Duration: once daily for 5 consecutive days every week up to 28 doses in 40 days
Outcomes Primary: active trachoma.
Secondary: TRIC-positive immunofluorescent inclusions.
Adverse effects: anorexia, nausea, vomiting or diarrhoea.
Notes Participants boarding.
Placebo with ’strong beneficial effect’.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment? Unclear risk Although the drugs were identical appear-
ance and taste and coded A/B (see below) it
was not clear how they were allocated, for
example, whether they were sequentially
numbered
Blinding?
Active trachoma
Unclear risk “Doxycycline capsules (50 mg) and a
placebo of identical appearance and taste
were used.Medicationswere coded asDrug
A orDrugB, and the identity remained un-
known to subjects, physicians and nursing
personnel until the results of all examina-
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tion had been recorded.“ (page 221)
However, since there was a marked
improvement in the doxycycline-treated
group and the drugs were only labelled A
or B, the identity of the active drugs may
well have been obvious well before the end
of the trial
Blinding?
Ocular Chlamydia trachomatis infection
Low risk “Doxycycline capsules (50 mg) and a
placebo of identical appearance and taste
were used.Medicationswere coded asDrug
A orDrugB, and the identity remained un-
known to subjects, physicians and nursing
personnel until the results of all examina-
tion had been recorded.“ (page 221)
Laboratory analyses will have been easier to
mask effectively,
Incomplete outcome data addressed?
Active trachoma
High risk 120 students randomised and 103 (86%)
followed up: 54 placebo and 49 active treat-
ment. However, not clear what the original
random allocations were
“The others had to be eliminated because
of definite gaps in intake of medication,
because serum levels or drug could not be
documented, or because they were unavail-
able for one or more follow-up examina-
tions“ (page 222)
Incomplete outcome data addressed?
Ocular Chlamydia trachomatis infection
High risk See above.
Free of selective reporting? Low risk Both outcomes of relevance to this review
reported.
Free of other bias? Low risk
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Lee 2007
Methods Allocation: random.
Unit of randomisation: village.
Masking:
participant - no,
provider - no,
outcome - no (active trachoma), yes (C.trachomatis infection).
Exclusions after randomisation: no.
Losses to follow up: no information.
Participants Country: Ethiopia.
Number randomised: 3 villages in each group; 170 children examined in treated villages
and 185 in control villages.
Age: 1 to 5 years.
Sex: not reported.
Clinical grading: Dawson 1981.
Lab tests: Amplicor polymerase chain reaction (PCR; Roche Diagnostics, Branchburg,
NJ)
Inclusion criteria:
Exclusion criteria:
Interventions TREATMENT: azithromycin “mass treatment” so presumablywhole community treated
not just the children.
Administration: oral.
Dose: not stated.
Duration: two doses per year.
COMPARISON: no treatment.
Outcomes Primary: ocular chlamydial infection.
Notes 3 villages randomly selected for treatment as part of national control programme. 3
villages randomly selected out of villages not yet enrolled in national programme for
examination as controls
Risk of bias
Bias Authors’ judgement Support for judgement
Blinding?
Active trachoma
High risk In treated villages children were given oral
antibiotic. In control villages, treatment
was planned for a later date. So children
would have knownwhether or not they had
been treated and probably the person con-
ducting the clinical examinations would
also have known which villages had been
treated
Blinding?
Ocular Chlamydia trachomatis infection
Low risk “All samples were processed in a masked
manner” (page 129).
“Samples and controls were labelled with
random numbers for processing by masked
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laboratory personnel.” (page 130)
Incomplete outcome data addressed?
Active trachoma
Unclear risk Study design - random selectionof 3 treated
villages and 3 as yet untreated villages in
a trachoma control program for survey -
meant that all clusters by definition com-
pleted the trial
No information on numbers of children in
villages and percentage seen in survey given
so difficult to tell
Incomplete outcome data addressed?
Ocular Chlamydia trachomatis infection
Unclear risk See above.
Free of selective reporting? Unclear risk Both microbiological and clinical out-
comes collected but only microbiological
outcomes reported.However, this appeared
to be the main purpose of the trial so it is
not clear that this was selective outcome re-
porting as such
Free of other bias? Low risk
Recruitment bias addressed? Unclear risk “All children1-5 years of agewere identified
through the census and requested to come
to a central locationwith a guardian.” (page
129)
No information given on response rates to
this request for participation
Baseline imbalances addressed? Unclear risk Stratified or pair-matched randomisation
of clusters was not employed. No baseline
characteristics other than prevalence of in-
fection (1) in the conjunctivae of children
and (2) in flies caught from children’s eyes
were reported
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Peach 1986
Methods Allocation: stratified randomisation.
Unit of randomisation: community but analysed as individuals
Masking:
participant - no,
provider - no,
outcome: no.
Exclusions after randomisation: no.
Losses to follow up: yes.
Participants Country: Australia.
Number randomised: 641.
Age: children 5 to 14 years (plus 5% under 5 and 5% over 14).
Sex: not reported.
Grading: local version with at least one follicle or some papillary hypertrophy being
positive.
No lab tests.
Interventions TREATMENT: oily tetracycline daily for 5 days once a month for 3 months
COMPARISON: no treatment.
Outcomes Primary: active trachoma.
Notes One arm of a larger trial with components face washing and face washing plus antibiotics
Risk of bias
Bias Authors’ judgement Support for judgement
Blinding?
Active trachoma
Unclear risk Topical antibiotics versus observation.
Communitieswill have knownwhich treat-
ment group
“The trachoma workers did not know what
treatment program, if any, had been allo-
cated to a particular community and com-
munities were visited in the same order in
which they had initially been screened.“
(page 76)
Incomplete outcome data addressed?
Active trachoma
Low risk No information on the clusters.
“Children lost to follow-up were assumed
to have follicles and were included in the
analysis on that basis” (page 76)
22/211 (10%) were lost to follow-up in
control communities. 34/374 (9%) lost to
follow-up in treated communities. These
were not large losses to followup and the as-
sumption that they all have active trachoma
is a conservative one which is why we have
put yes here
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Incomplete outcome data addressed?
Ocular Chlamydia trachomatis infection
Unclear risk No data on ocular infection reported.
Free of selective reporting? Low risk Only clinical outcomes reported but no in-
dication of any collection of data on micro-
biological outcomes
Free of other bias? Low risk
Resnikoff 1995
Methods Allocation: random.
Unit of randomisation: village.
Masking:
participant - no,
provider - no,
outcome - no.
Exclusions after randomisation: no information.
Losses to follow-up: no information.
Participants Country: Mali.
Number randomised: 4 villages randomly allocated to four different interventions. 2
villages only eligible for inclusion in this review.
Age: 1 to 5 years.
Sex: not reported.
Clinical grading: Thylefors 1987.
Lab tests: none.
Inclusion criteria: all inhabitants.
Exclusion criteria: none.
Interventions TREATMENT: 1% oxytetracycline eye drop solution (Innolyre). 1 drop 4 times daily
for 7 days a month for 6 months. Directly supervised by village workers
COMPARISON: no treatment.
Outcomes Primary: active trachoma.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Blinding?
Active trachoma
High risk This was not reported so we have assumed
that it did not happen as treatment was
compared to no treatment. The study was
described as “open controlled clinical trial”
(page 103)
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Incomplete outcome data addressed?
Active trachoma
High risk “At the initial examination, 1810 subjects
were enrolled and examined” (page 104).
Of these, 424 were from the community
treated with topical antibiotics (village 2)
and 476 were from the control community
(village 4) (table 2 page 109)
“A total of 347 subjects with active tra-
choma were included in the clinical trial.
Two hundred and sixty five (76%) of these
subjects were successfully followed for 6
months and were included in the analysis
of the results.” (page 105)
However, the distribution of these cases by
village is not reported. Using figure 1 (page
109) we can estimate that there were 89
cases of active trachoma in treatment com-
munity and 90 cases in control commu-
nity. The “cure rate” in treatment village
was 82% (estimated 73 people cured) and
36% in control community (estimated 33
people cured).
No information was given on possible rea-
sons for loss to follow up
Incomplete outcome data addressed?
Ocular Chlamydia trachomatis infection
Unclear risk No data on ocular infection reported.
Free of selective reporting? Low risk Only clinical outcomes reported but no in-
dication thatmicrobiological data collected
Free of other bias? Low risk
Recruitment bias addressed? Unclear risk “With the permissionof administrative and
traditional authorities, all inhabitants of
these four villages were surveyed” (page
102).
No other information on recruitment in
particular no indication as to response rates
of the survey in the villages concerned
Baseline imbalances addressed? High risk “Four villages, matched for size and epi-
demiological, economic and social condi-
tions, were included in the study. All vil-
lages were situated the same distance from
the health centre and each village possessed
a school and was equipped with boreholes.
” (page 102) (NB: two of these villages
concerned health education and data from
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these not included in this review)
“The age and sex distribution was identi-
cal in all four villages” (page 103). Table 2
(page 109) shows the sex distribution (46%
male in treatment community and 51%
male in control community). No data on
age distribution
Baseline prevalence of active trachoma (fig-
ure 1, page 109) just over 20% in treatment
community and just under 20% in control
community
Shukla 1966
Methods Type of trial: clinical.
Allocation: random.
Unit of randomisation: individual.
Masking:
participant - no,
provider - no,
outcome: - unclear.
Exclusions after randomisation: no.
Losses to follow up: none.
Unusual study design: four-armed trial with factorial design
Participants Country: India.
Number randomised: 349.
Age (ave.): 5 to 13 years.
Sex: not reported.
Clinical grading: WHO 1962.
Lab tests: none.
Inclusion criteria: active trachoma, schooling at a study school.
Exclusion criteria: none.
Interventions TREATMENT 1: sulphafurazole + sulphadimethoxine.
Administration: topical + oral.
Dose: 15%/100 mg/kg.
Duration: twice daily for 5 consecutive days every month for 5 months/bi-weekly for 5
months
TREATMENT 2: sulphadimethoxine.
Administration: oral.
Dose: 100 mg/kg.
Duration: biweekly or weekly dose for 5 months.
TREATMENT 3: sulphafurazole.
Administration: topical.
Dose: 15%.
Duration: twice daily for 5 consecutive days every month for 5 months
COMPARISON: no treatment.
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Outcomes Primary: active trachoma.
Secondary: -
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment? Unclear risk No information given .
Blinding?
Active trachoma
High risk No information given and treatments dif-
ferent in the different groups so study un-
likely to have been blinded. However,
study is described as “double-blind study”
Incomplete outcome data addressed?
Active trachoma
Unclear risk Apparently 100% follow upwith exception
of one group B1 at five months where 35/
41 seen
Incomplete outcome data addressed?
Ocular Chlamydia trachomatis infection
Unclear risk No data on ocular infection reported.
Free of selective reporting? Low risk Only clinical outcomes reported but no in-
dication thatmicrobiological data collected
Free of other bias? Unclear risk Report too brief to assess.
Tabbara 1996
Methods Type of trial: clinical.
Allocation: random.
Unit of randomisation: individual.
Masking:
participant - no,
provider - no,
outcome - yes.
Exclusions after randomisation: no.
Losses to follow up: absence.
Participants Country: Saudi Arabia.
Number randomised: 64.
Age (ave.): 6 to 14 years (11.1).
Sex: not reported.
Clinical grading: Dawson 1981.
Lab tests: conjunctival scrapings for inclusion bodies/cells/organisms/mucus; IFAT for
free elementary bodies
Inclusion criteria: active trachoma, schooling in study village.
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Exclusion criteria: none.
Interventions TREATMENT: azithromycin.
Administration: oral.
Dose: 20 mg/kg.
Duration: 1 dose.
COMPARISON: tetracycline.
Administration: topical.
Dose: 1%.
Duration: twice daily for 5 consecutive days per week over 6 weeks
Outcomes Primary: active trachoma.
Secondary: intraepithelial cell inclusion bodies, free elementary bodies.
Adverse effects: none.
Notes Case definition not clear (probable diagnosis of trachoma based on cytology, definitive
diagnosis of trachoma based on microscopical assessment of scrapings)
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment? Unclear risk Not reported.
Blinding?
Active trachoma
Unclear risk Study was described as “single-masked”
(page 843). Patients were aware of therapy
because oral versus topical treatment
“The examiner was unaware of the treat-
ment allocation at the time of the exami-
nation” (page 843)
No information on whether the masking
was effective - for example, did the patients
tell the examinerswhich treatment they had
received?
Blinding?
Ocular Chlamydia trachomatis infection
Low risk “Conjunctival scrapings were obtained
from each patient before initiation of ther-
apy” “The slides were coded and masked to
the reader” (page 843)
Incomplete outcome data addressed?
Active trachoma
Unclear risk It was not clear how many randomised to
treatment/control but reported percentages
suggest that it was 32 in each group
8 weeks: treatment 2/32 (6.3%) and con-
trol 5/32 (15.6%) lost to follow up
12 weeks: treatment 1/32 (3.1%) and con-
trol 3/32 (9.4%) lost to follow up
24 weeks: treatment 2/32 (6.3%) and con-
trol 6/32 (18.8%) lost to follow up
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Higher loss to follow up in control group
but actual numbers not very large. No in-
dication as to reason for not being seen.We
have put “unclear” here because not sure
what the effect of these missing data will be
Incomplete outcome data addressed?
Ocular Chlamydia trachomatis infection
Unclear risk See above.
Free of selective reporting? Low risk Both outcomes of relevance to this review
reported.
Free of other bias? Low risk
TANA 2009
Methods Cluster-randomised trial. 72 subkebeles (government defined units) randomised to treat-
ment or delayed treatment. Six treatment groups of 12 subkebeles each
Participants People resident in these communities. Different members of the population were treated
according to the treatment schedule being tested (see interventions below)
Interventions (1) Children aged 1-10 were offered oral azithromycin 4 times per year. Height based
dosing equivalent to roughly 20 mg/Kg. Treatment directly observed. Children younger
than1 yearwere offered a 6-week course of topical tetracycline 1%(not directly observed).
Children and adults aged 11 years and above were assessed for ocular chlamydial infection
at 12 months
(2) Treatment was delayed and delivered at 12 months. Children and adults aged 11
years and above were assessed for ocular chlamydial infection at 12 months
(3) Annual mass treatment. All individuals aged 1 year and older were offered oral
azithromycin as for (1). Women self-reporting as pregnant or children under 1 year
offered topical tetracycline
(4) Biannual mass treatment as for (3).
[Treatment groups (5) and (6) refer to evaluation of benefits of added Intensive latrine
construction and are outwith the remit of this review).]
The following information about the overall study aims was obtained from the trial
registration information on ClinicalTrials.gov
“The proposed study is a group-randomized trial to determine the frequency and treatment
target of community-wide mass antibiotic treatment to eliminate trachoma. We will also
study the impact of community-wide antibiotic distribution on antibiotic-resistance in pneu-
mococcus. Communities in Goncha Siso Enese district of East Gojam Zone, Ethiopia will
be randomly assigned to different treatment schemes and monitored to study the following
research questions:
Specific Aim 1. To determine whether biannual mass treatments is more likely to eliminate
ocular chlamydia from hyper-endemic communities than annual mass treatments.
Specific Aim 2. To determine whether children form a core group for the transmission of
trachoma.
Specific Aim 3. To determine whether latrine construction prevents the return of infection
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into a community after mass treatment.
Specific Aim 4. To determine the effect of mass azithromycin treatments on antibiotic resistance
in pneumococcus and the reduction in mortality.”
As at April 2010, there are two publications available from this study. House et al
addresses study aim 2 but has a slightly different emphasis - “Assessment of herd protection
against trachoma due to repeated mass antibiotic distributions: a cluster-randomised trial”.
Porco et al address part of aim 4 looking at mortality in Ethiopian children. “Effect of
Mass Distribution of Azithromycin for Trachoma Control on Overall Mortality in Ethiopian
Children”.
Outcomes The following information about outcomes was obtained from the trial registration
information on ClinicalTrials.gov
“Primary Outcome Measures:
• The average prevalence of ocular chlamydia infection in communities in an arm as
determined by pooled NAAT (Nucleic Acid Amplification Test)(at 42 months for Aim 1, at
12 months for Aim 2, post-treatment relative to pre-treatment for Aim 3) [ Time Frame: 42
months ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
• Clinical active trachoma in community, as determined by the WHO simplified
grading system [ Time Frame: 42 months ] [ Designated as safety issue: No ]
• Childhood (>= 1 year of age) mortality, analyzed as 1-5, 6-10 years of age, and total [
Time Frame: 42 months ] [ Designated as safety issue: No ]
• Macrolide resistance in pneumococcus (% resistance over time, clustered by
randomization unit) [ Time Frame: 42 months ] [ Designated as safety issue: No ]”
Notes ClnicalTrials.gov identifier: NCT00322972
TANA: Trachoma Amelioration in Northern Amhara
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment? Low risk “The 72 subkebeles were randomly as-
signed to one of six groups of 12 sub-
kebeles each, forming three separate tra-
choma-specific comparisons (generationby
KJRwith RANDOM() and SORT() in Ex-
cel [version 2003], implementation by BA,
concealed until assignment).” (House et al
Lancet 2009, page 1112).
Blinding?
Active trachoma
Unclear risk “Censuses for all study communities were
undertaken by trained health-care person-
nel whowere blinded to study group and to
the prevalence of ocular chlamydial infec-
tion”.House et al Lancet 2009, page 1112.
However, no mention of masking of clini-
cal observers.
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Blinding?
Ocular Chlamydia trachomatis infection
Low risk “Laboratory personnel were blinded to in-
dividual, community, and treatment-group
identifications. Since dilution effects and
underestimation due to pooling could the-
oretically occur, all communities had to be
processed in an identical way, and complete
masking of laboratory personnel had to be
maintained.” (House et al Lancet 2009, page
1114).
Incomplete outcome data addressed?
Active trachoma
Unclear risk Data not reported.
Incomplete outcome data addressed?
Ocular Chlamydia trachomatis infection
Low risk Random sample selected for measurement
of ocular infection. 637/720 (88%) chil-
dren seen in “children-treated” group, 618/
720 (86%) children seen in control group
(delayed treatment) and 600/720 (83%)
children seen in mass treatment group.
Equivalent measures for children>=11 and
adults: 561/720 (78%); 550/720 (76%);
599/720 (83%)
Free of selective reporting? Low risk Currently data available for aim 2 of origi-
nal study. Outcomes reported match those
specified at trial registration
Free of other bias? Low risk
Recruitment bias addressed? Low risk No information reported however we be-
lieve that this is unlikely because in all arms
treatment was offered at the same time as
assessment
Baseline imbalances addressed? Low risk Pre-treatment age, sex, ocular and clinical
infection in children reported at baseline
for treated communities and 12months for
untreated communities. No major imbal-
ances reported. (House et al 2009. Table 1)
.
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Methods Allocation: random.
Unit of randomisation: individual.
Masking:
participant: no,
provider: no,
outcome: yes.
Exclusions after randomisation: unclear.
Losses to follow up: unclear.
Unusual study design: combined vaccine and therapy trial. Review considers groups with
placebo-vaccine
Participants Country: Taiwan.
Number randomised: 322.
Age (ave.): primary school age.
Sex: not reported.
Clinical grading: Modified McCallan classification.
Lab tests: none.
Inclusion criteria: active trachoma.
Exclusion criteria: none.
Interventions TREATMENT: tetracycline.
Administration: topical.
Dose: 1%.
Duration: twice daily for 6 consecutive days per week for 6 weeks
COMPARISON: no treatment.
Outcomes Primary: active trachoma.
Secondary: none.
Adverse effects: not assessed.
Notes Only trachoma-positives included, but table does not show this. Numbers for analysis
calculated from percentages given
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment? Unclear risk Not reported.
Blinding?
Active trachoma
Unclear risk “The ophthalmologists making the eye ex-
aminations at no time knew to which vac-
cine or treatment group the subject be-
longed nor what his previous diagnosis had
been” (page 1578)
“Placebo therapy was not employed” (page
1578).
No discussion as to whether the ophthal-
mologists might have been unmasked be-
cause the patients knew their treatment
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Woolridge 1967 (Continued)
group
Incomplete outcome data addressed?
Active trachoma
Unclear risk No information on completeness of follow
up.
Incomplete outcome data addressed?
Ocular Chlamydia trachomatis infection
Unclear risk Data on ocular infection not reported.
Free of selective reporting? Low risk Active trachoma only reported but no indi-
cation any data collected on C. trachomatis
infection.
Free of other bias? Low risk
ITT - intention to treat
mg/kg - milligrams per kilogram of body weight
LCR - ligase chain reaction
PCR - polymerase chain reaction
Ave. - average
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Abdou 2007 Prevalence study only.
Assaad 1968 Concealment of allocation: C (twice randomisation among two groups)
Astle 2006 Prevalence study only.
Babbar 1982 No comparison group receiving placebo or no treatment.
Biebesheimer 2009 No comparator villages.
Bietti 1967 Review only.
Broman 2006 Not randomised controlled trial.
Cerulli 1983 No evidence of randomisation.
Chumbley 1988 No comparison group receiving placebo or no treatment.
Daghfous 1974 No evidence of randomisation.
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(Continued)
Daghfous 1985 No comparison group receiving placebo or no treatment.
No evidence of randomisation.
Darougar 1980a No comparison group receiving placebo or no treatment.
Darougar 1981 No comparison group.
Dawson 1967a Allocation concealment inadequate (alternation).
Dawson 1967b Allocation concealment inadequate (alternation).
Dawson 1968 No evidence of randomisation.
Dawson 1971 Allocation concealment inadequate (alternation).
Dawson 1972a No evidence of randomisation.
Dawson 1972b No evidence of randomisation.
Dawson 1974a No evidence of randomisation.
Dawson 1974b Allocation concealment inadequate.
Dawson 1975a Allocation concealment inadequate.
Dawson 1981a No proper control group (previously treated children who did not receive treatment during actual trial)
Dawson 1982 No comparison group receiving placebo or no treatment.
Edwards 2006 Health education intervention.
Gower 2006 Not randomised controlled trial.
Gupta 1966 No evidence of randomisation.
Gupta 1968 No comparison group receiving placebo or no treatment.
Guzey 2000 Inclusion criteria of participants non-specific. They had bilateral trachoma or showed symptoms (not described)
Hasan 1976 No comparison group receiving placebo or no treatment.
Humet 1989 No eye outcome.
Isenberg 2002 Study not carried out in a trachoma endemic area.
Ji 1986 No trial report.
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(Continued)
Kamiya 1956 Lack of comparison villages.
Khandekar 2006 Prevalence study.
Lakew 2009 No comparator villages
Litricin 1968 No comparison group.
Mesfin 2006 Prevalence study
Mohan 1982 No evidence of randomisation.
Nabli 1988 No comparison group.
Ngondi 2006a Prevalence study.
Ngondi 2006b No antibiotic/no antibiotic comparison.
Nisbet 1979 Placebo invalid.
Obikili 1988 No comparison group.
Putschky 2006 No eye outcome.
Reinhards 1959 No comparison group.
Resnikoff 1994 No comparison group.
Schemann 2007 Comparison of different treatment targeting strategies therefore does not meet inclusion criteria for review
Tabbara 1988 Randomisation was by eye and not patient. It was not possible to determine the individual patient outcome
Toufic 1968 Report of control campaigns not trials.
Wadia 1980 No comparison group.
Werner 1977 No comparison group.
No evidence of randomisation.
West 2006 Test efficacy of insecticide.
Whitcher 1974 No evidence of randomisation.
Zhang 2006 No appropriate control group.
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D A T A A N D A N A L Y S E S
Comparison 1. Any antibiotic versus control (individuals)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Active trachoma at three months 9 1961 Risk Ratio (M-H, Random, 95% CI) 0.78 [0.69, 0.89]
2 Ocular C.trachomatis infection
at three months
4 297 Risk Ratio (M-H, Random, 95% CI) 0.81 [0.63, 1.04]
3 Active trachoma at 12 months 4 1035 Risk Ratio (M-H, Random, 95% CI) 0.74 [0.55, 1.00]
4 Ocular C. trachomatis infection
at 12 months
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
Comparison 2. Subgroup analysis: oral and topical antibiotics versus control (individuals)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Active trachoma at three months 9 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Oral antibiotic 6 599 Risk Ratio (M-H, Random, 95% CI) 0.81 [0.67, 0.97]
1.2 Topical antibiotic 6 1478 Risk Ratio (M-H, Random, 95% CI) 0.82 [0.72, 0.92]
2 Ocular C. trachomatis infection
at three months
4 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Oral antibiotic 4 259 Risk Ratio (M-H, Fixed, 95% CI) 0.85 [0.66, 1.11]
2.2 Topical antibiotic 1 85 Risk Ratio (M-H, Fixed, 95% CI) 0.18 [0.02, 1.37]
3 Active trachoma at 12 months 4 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 Oral antibiotic 3 429 Risk Ratio (M-H, Fixed, 95% CI) 0.87 [0.76, 1.00]
3.2 Topical antibiotic 4 724 Risk Ratio (M-H, Fixed, 95% CI) 0.79 [0.71, 0.88]
4 Ocular C. trachomatis infection
at 12 months
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 Oral antibiotic 1 91 Risk Ratio (M-H, Fixed, 95% CI) 0.36 [0.10, 1.23]
4.2 Topical antibiotic 1 85 Risk Ratio (M-H, Fixed, 95% CI) 0.14 [0.02, 1.04]
Comparison 3. Oral versus topical antibiotics (individuals)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Active trachoma at three months 6 953 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.82, 1.18]
2 Ocular C. trachomatis infection
at three months
3 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
3 Active trachoma at 12 months 5 886 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.75, 1.15]
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4 Ocular C. trachomatis infection
at 12 months
2 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
Comparison 4. Oral azithromycin versus topical tetracycline (individuals)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Active trachoma at three months 3 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2 Ocular C. trachomatis infection
at three months
2 Risk Ratio (M-H, Random, 95% CI) Totals not selected
3 Active trachoma at 12 months 2 447 Risk Ratio (M-H, Fixed, 95% CI) 0.76 [0.59, 0.99]
4 Ocular C. trachomatis infection
at 12 months
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
Comparison 5. Oral azithromycin versus control (communities)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Active trachoma at 12 months 2 Risk Ratio (M-H, Random, 95% CI) Totals not selected
2 Ocular C. trachomatis infection
at 12 months
4 4345 Risk Ratio (M-H, Random, 95% CI) 0.35 [0.21, 0.60]
Comparison 6. Oral azithromycin versus topical tetracycline (communities)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Active trachoma at 3 months 3 Risk Ratio (M-H, Random, 95% CI) Totals not selected
2 Ocular C. trachomatis infection
at 3 months
3 Risk Ratio (M-H, Random, 95% CI) Totals not selected
3 Active trachoma at 12 months 3 Risk Ratio (M-H, Random, 95% CI) Totals not selected
4 Ocular C. trachomatis infection
at 12 months
3 Risk Ratio (M-H, Random, 95% CI) Totals not selected
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Analysis 1.1. Comparison 1 Any antibiotic versus control (individuals), Outcome 1 Active trachoma at
three months.
Review: Antibiotics for trachoma
Comparison: 1 Any antibiotic versus control (individuals)
Outcome: 1 Active trachoma at three months
Study or subgroup Antibiotic Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Attiah 1973 84/152 58/76 13.0 % 0.72 [ 0.60, 0.88 ]
Darougar 1980 61/79 34/45 12.4 % 1.02 [ 0.83, 1.25 ]
Dawson 1969 Sherman 1/15 1/14 0.2 % 0.93 [ 0.06, 13.54 ]
Dawson 1969 Stewart 6/18 15/18 2.8 % 0.40 [ 0.20, 0.79 ]
Foster 1966 165/218 88/107 16.1 % 0.92 [ 0.82, 1.03 ]
Hoshiwara 1973 28/49 44/54 9.8 % 0.70 [ 0.53, 0.92 ]
Peach 1986 216/340 138/189 16.0 % 0.87 [ 0.77, 0.98 ]
Shukla 1966 113/223 36/42 13.5 % 0.59 [ 0.49, 0.71 ]
Woolridge 1967 139/202 103/120 16.0 % 0.80 [ 0.71, 0.90 ]
Total (95% CI) 1296 665 100.0 % 0.78 [ 0.69, 0.89 ]
Total events: 813 (Antibiotic), 517 (Control)
Heterogeneity: Tau2 = 0.02; Chi2 = 29.38, df = 8 (P = 0.00027); I2 =73%
Test for overall effect: Z = 3.81 (P = 0.00014)
0.1 0.2 0.5 1 2 5 10
Favours antibiotic Favours control
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Analysis 1.2. Comparison 1 Any antibiotic versus control (individuals), Outcome 2 Ocular C.trachomatis
infection at three months.
Review: Antibiotics for trachoma
Comparison: 1 Any antibiotic versus control (individuals)
Outcome: 2 Ocular C.trachomatis infection at three months
Study or subgroup Antibiotic Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Darougar 1980 8/82 7/47 7.1 % 0.66 [ 0.25, 1.69 ]
Dawson 1969 Sherman 7/15 10/14 15.9 % 0.65 [ 0.35, 1.23 ]
Dawson 1969 Stewart 11/18 14/18 32.4 % 0.79 [ 0.50, 1.22 ]
Hoshiwara 1973 24/49 29/54 44.6 % 0.91 [ 0.62, 1.33 ]
Total (95% CI) 164 133 100.0 % 0.81 [ 0.63, 1.04 ]
Total events: 50 (Antibiotic), 60 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.03, df = 3 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 1.68 (P = 0.093)
0.1 0.2 0.5 1 2 5 10
Favours antibiotic Favours control
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Analysis 1.3. Comparison 1 Any antibiotic versus control (individuals), Outcome 3 Active trachoma at 12
months.
Review: Antibiotics for trachoma
Comparison: 1 Any antibiotic versus control (individuals)
Outcome: 3 Active trachoma at 12 months
Study or subgroup Antibiotic Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Darougar 1980 43/82 33/47 22.7 % 0.75 [ 0.57, 0.99 ]
Foster 1966 145/218 68/107 25.9 % 1.05 [ 0.88, 1.24 ]
Shukla 1966 91/217 35/42 24.9 % 0.50 [ 0.41, 0.62 ]
Woolridge 1967 121/202 95/120 26.5 % 0.76 [ 0.65, 0.88 ]
Total (95% CI) 719 316 100.0 % 0.74 [ 0.55, 1.00 ]
Total events: 400 (Antibiotic), 231 (Control)
Heterogeneity: Tau2 = 0.08; Chi2 = 29.16, df = 3 (P<0.00001); I2 =90%
Test for overall effect: Z = 1.96 (P = 0.050)
0.1 0.2 0.5 1 2 5 10
Favours antibiotic Favours control
Analysis 1.4. Comparison 1 Any antibiotic versus control (individuals), Outcome 4 Ocular C. trachomatis
infection at 12 months.
Review: Antibiotics for trachoma
Comparison: 1 Any antibiotic versus control (individuals)
Outcome: 4 Ocular C. trachomatis infection at 12 months
Study or subgroup Antibiotic Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Darougar 1980 4/82 9/47 0.25 [ 0.08, 0.78 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 4 (Antibiotic), 9 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.1 0.2 0.5 1 2 5 10
Favours antibiotic Favours control
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Analysis 2.1. Comparison 2 Subgroup analysis: oral and topical antibiotics versus control (individuals),
Outcome 1 Active trachoma at three months.
Review: Antibiotics for trachoma
Comparison: 2 Subgroup analysis: oral and topical antibiotics versus control (individuals)
Outcome: 1 Active trachoma at three months
Study or subgroup Antibiotic Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Oral antibiotic
Darougar 1980 32/42 34/45 21.7 % 1.01 [ 0.80, 1.28 ]
Dawson 1969 Sherman 1/15 1/14 0.5 % 0.93 [ 0.06, 13.54 ]
Dawson 1969 Stewart 6/18 15/18 5.9 % 0.40 [ 0.20, 0.79 ]
Foster 1966 86/112 88/107 28.7 % 0.93 [ 0.82, 1.07 ]
Hoshiwara 1973 28/49 44/54 19.3 % 0.70 [ 0.53, 0.92 ]
Shukla 1966 53/83 36/42 23.9 % 0.74 [ 0.61, 0.91 ]
Subtotal (95% CI) 319 280 100.0 % 0.81 [ 0.67, 0.97 ]
Total events: 206 (Antibiotic), 218 (Control)
Heterogeneity: Tau2 = 0.03; Chi2 = 12.52, df = 5 (P = 0.03); I2 =60%
Test for overall effect: Z = 2.26 (P = 0.024)
2 Topical antibiotic
Attiah 1973 84/152 58/76 15.8 % 0.72 [ 0.60, 0.88 ]
Darougar 1980 29/37 34/45 13.0 % 1.04 [ 0.82, 1.32 ]
Foster 1966 79/106 88/107 19.2 % 0.91 [ 0.79, 1.04 ]
Peach 1986 216/340 138/189 20.9 % 0.87 [ 0.77, 0.98 ]
Shukla 1966 29/62 36/42 10.3 % 0.55 [ 0.41, 0.73 ]
Woolridge 1967 139/202 103/120 20.9 % 0.80 [ 0.71, 0.90 ]
Subtotal (95% CI) 899 579 100.0 % 0.82 [ 0.72, 0.92 ]
Total events: 576 (Antibiotic), 457 (Control)
Heterogeneity: Tau2 = 0.01; Chi2 = 15.77, df = 5 (P = 0.01); I2 =68%
Test for overall effect: Z = 3.30 (P = 0.00097)
0.1 0.2 0.5 1 2 5 10
Favours antibiotic Favours control
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Analysis 2.2. Comparison 2 Subgroup analysis: oral and topical antibiotics versus control (individuals),
Outcome 2 Ocular C. trachomatis infection at three months.
Review: Antibiotics for trachoma
Comparison: 2 Subgroup analysis: oral and topical antibiotics versus control (individuals)
Outcome: 2 Ocular C. trachomatis infection at three months
Study or subgroup Antibiotic Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Oral antibiotic
Darougar 1980 7/44 7/47 11.5 % 1.07 [ 0.41, 2.80 ]
Dawson 1969 Sherman 7/15 10/14 17.6 % 0.65 [ 0.35, 1.23 ]
Dawson 1969 Stewart 11/18 14/18 23.8 % 0.79 [ 0.50, 1.22 ]
Hoshiwara 1973 24/49 29/54 47.0 % 0.91 [ 0.62, 1.33 ]
Subtotal (95% CI) 126 133 100.0 % 0.85 [ 0.66, 1.11 ]
Total events: 49 (Antibiotic), 60 (Control)
Heterogeneity: Chi2 = 1.14, df = 3 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 1.17 (P = 0.24)
2 Topical antibiotic
Darougar 1980 1/38 7/47 100.0 % 0.18 [ 0.02, 1.37 ]
Subtotal (95% CI) 38 47 100.0 % 0.18 [ 0.02, 1.37 ]
Total events: 1 (Antibiotic), 7 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.66 (P = 0.098)
0.1 0.2 0.5 1 2 5 10
Favours antibiotic Favours control
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Analysis 2.3. Comparison 2 Subgroup analysis: oral and topical antibiotics versus control (individuals),
Outcome 3 Active trachoma at 12 months.
Review: Antibiotics for trachoma
Comparison: 2 Subgroup analysis: oral and topical antibiotics versus control (individuals)
Outcome: 3 Active trachoma at 12 months
Study or subgroup Antibiotic Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Oral antibiotic
Darougar 1980 24/44 33/47 21.7 % 0.78 [ 0.56, 1.08 ]
Foster 1966 80/112 68/107 47.4 % 1.12 [ 0.93, 1.35 ]
Shukla 1966 36/77 35/42 30.9 % 0.56 [ 0.43, 0.74 ]
Subtotal (95% CI) 233 196 100.0 % 0.87 [ 0.76, 1.00 ]
Total events: 140 (Antibiotic), 136 (Control)
Heterogeneity: Chi2 = 17.63, df = 2 (P = 0.00015); I2 =89%
Test for overall effect: Z = 1.90 (P = 0.057)
2 Topical antibiotic
Darougar 1980 19/38 33/47 11.4 % 0.71 [ 0.49, 1.03 ]
Foster 1966 65/106 68/107 26.2 % 0.96 [ 0.78, 1.19 ]
Shukla 1966 35/62 35/42 16.2 % 0.68 [ 0.52, 0.88 ]
Woolridge 1967 121/202 95/120 46.2 % 0.76 [ 0.65, 0.88 ]
Subtotal (95% CI) 408 316 100.0 % 0.79 [ 0.71, 0.88 ]
Total events: 240 (Antibiotic), 231 (Control)
Heterogeneity: Chi2 = 5.58, df = 3 (P = 0.13); I2 =46%
Test for overall effect: Z = 4.33 (P = 0.000015)
0.1 0.2 0.5 1 2 5 10
Favours antibiotic Favours control
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Analysis 2.4. Comparison 2 Subgroup analysis: oral and topical antibiotics versus control (individuals),
Outcome 4 Ocular C. trachomatis infection at 12 months.
Review: Antibiotics for trachoma
Comparison: 2 Subgroup analysis: oral and topical antibiotics versus control (individuals)
Outcome: 4 Ocular C. trachomatis infection at 12 months
Study or subgroup Antibiotic Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Oral antibiotic
Darougar 1980 3/44 9/47 100.0 % 0.36 [ 0.10, 1.23 ]
Subtotal (95% CI) 44 47 100.0 % 0.36 [ 0.10, 1.23 ]
Total events: 3 (Antibiotic), 9 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.63 (P = 0.10)
2 Topical antibiotic
Darougar 1980 1/38 9/47 100.0 % 0.14 [ 0.02, 1.04 ]
Subtotal (95% CI) 38 47 100.0 % 0.14 [ 0.02, 1.04 ]
Total events: 1 (Antibiotic), 9 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.92 (P = 0.054)
0.1 0.2 0.5 1 2 5 10
Favours antibiotic Favours control
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Analysis 3.1. Comparison 3 Oral versus topical antibiotics (individuals), Outcome 1 Active trachoma at
three months.
Review: Antibiotics for trachoma
Comparison: 3 Oral versus topical antibiotics (individuals)
Outcome: 1 Active trachoma at three months
Study or subgroup Oral antibiotic Topical antibiotic Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bowman 2000 48/152 68/139 16.4 % 0.65 [ 0.48, 0.86 ]
Darougar 1980 32/42 29/37 18.9 % 0.97 [ 0.77, 1.23 ]
Dawson 1997 76/118 28/42 18.2 % 0.97 [ 0.75, 1.24 ]
Foster 1966 86/112 79/106 23.8 % 1.03 [ 0.89, 1.20 ]
Shukla 1966 53/83 29/62 15.3 % 1.37 [ 1.00, 1.86 ]
Tabbara 1996 15/31 12/29 7.4 % 1.17 [ 0.66, 2.06 ]
Total (95% CI) 538 415 100.0 % 0.98 [ 0.82, 1.18 ]
Total events: 310 (Oral antibiotic), 245 (Topical antibiotic)
Heterogeneity: Tau2 = 0.03; Chi2 = 13.48, df = 5 (P = 0.02); I2 =63%
Test for overall effect: Z = 0.18 (P = 0.85)
0.1 0.2 0.5 1 2 5 10
Favours oral Favours topical
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Analysis 3.2. Comparison 3 Oral versus topical antibiotics (individuals), Outcome 2 Ocular C. trachomatis
infection at three months.
Review: Antibiotics for trachoma
Comparison: 3 Oral versus topical antibiotics (individuals)
Outcome: 2 Ocular C. trachomatis infection at three months
Study or subgroup Oral antibiotic Topical antibiotic Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Darougar 1980 7/44 1/38 6.05 [ 0.78, 46.95 ]
Dawson 1997 5/119 3/41 0.57 [ 0.14, 2.30 ]
Tabbara 1996 6/30 4/26 1.30 [ 0.41, 4.11 ]
0.1 0.2 0.5 1 2 5 10
Favours oral Favours topical
Analysis 3.3. Comparison 3 Oral versus topical antibiotics (individuals), Outcome 3 Active trachoma at 12
months.
Review: Antibiotics for trachoma
Comparison: 3 Oral versus topical antibiotics (individuals)
Outcome: 3 Active trachoma at 12 months
Study or subgroup Oral antibiotic Topical antibiotic Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bowman 2000 32/149 45/139 16.4 % 0.66 [ 0.45, 0.98 ]
Darougar 1980 24/44 19/38 15.2 % 1.09 [ 0.72, 1.66 ]
Dawson 1997 60/117 24/42 20.3 % 0.90 [ 0.65, 1.23 ]
Foster 1966 80/112 65/106 28.3 % 1.16 [ 0.96, 1.41 ]
Shukla 1966 36/77 35/62 19.8 % 0.83 [ 0.60, 1.14 ]
Total (95% CI) 499 387 100.0 % 0.93 [ 0.75, 1.15 ]
Total events: 232 (Oral antibiotic), 188 (Topical antibiotic)
Heterogeneity: Tau2 = 0.03; Chi2 = 9.13, df = 4 (P = 0.06); I2 =56%
Test for overall effect: Z = 0.65 (P = 0.52)
0.1 0.2 0.5 1 2 5 10
Favours oral Favours topical
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Analysis 3.4. Comparison 3 Oral versus topical antibiotics (individuals), Outcome 4 Ocular C. trachomatis
infection at 12 months.
Review: Antibiotics for trachoma
Comparison: 3 Oral versus topical antibiotics (individuals)
Outcome: 4 Ocular C. trachomatis infection at 12 months
Study or subgroup Oral antibiotic Topical antibiotic Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Darougar 1980 3/44 1/38 2.59 [ 0.28, 23.88 ]
Dawson 1997 8/105 5/33 0.50 [ 0.18, 1.43 ]
0.1 0.2 0.5 1 2 5 10
Favours oral Favours topical
Analysis 4.1. Comparison 4 Oral azithromycin versus topical tetracycline (individuals), Outcome 1 Active
trachoma at three months.
Review: Antibiotics for trachoma
Comparison: 4 Oral azithromycin versus topical tetracycline (individuals)
Outcome: 1 Active trachoma at three months
Study or subgroup Oral azithromycin Topical tetracycline Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bowman 2000 48/152 68/139 0.65 [ 0.48, 0.86 ]
Dawson 1997 76/118 28/42 0.97 [ 0.75, 1.24 ]
Tabbara 1996 15/31 12/29 1.17 [ 0.66, 2.06 ]
0.1 0.2 0.5 1 2 5 10
Favours azithromycin Favours tetracycline
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Analysis 4.2. Comparison 4 Oral azithromycin versus topical tetracycline (individuals), Outcome 2 Ocular
C. trachomatis infection at three months.
Review: Antibiotics for trachoma
Comparison: 4 Oral azithromycin versus topical tetracycline (individuals)
Outcome: 2 Ocular C. trachomatis infection at three months
Study or subgroup Oral azithromycin Topical tetracycline Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Dawson 1997 5/119 3/41 0.57 [ 0.14, 2.30 ]
Tabbara 1996 6/30 4/26 1.30 [ 0.41, 4.11 ]
0.1 0.2 0.5 1 2 5 10
Favours azithromycin Favours tetracycline
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Analysis 4.3. Comparison 4 Oral azithromycin versus topical tetracycline (individuals), Outcome 3 Active
trachoma at 12 months.
Review: Antibiotics for trachoma
Comparison: 4 Oral azithromycin versus topical tetracycline (individuals)
Outcome: 3 Active trachoma at 12 months
Study or subgroup Oral azithromycin Topical tetracycline Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bowman 2000 32/149 45/139 56.9 % 0.66 [ 0.45, 0.98 ]
Dawson 1997 60/117 24/42 43.1 % 0.90 [ 0.65, 1.23 ]
Total (95% CI) 266 181 100.0 % 0.76 [ 0.59, 0.99 ]
Total events: 92 (Oral azithromycin), 69 (Topical tetracycline)
Heterogeneity: Chi2 = 1.50, df = 1 (P = 0.22); I2 =33%
Test for overall effect: Z = 2.07 (P = 0.038)
0.1 0.2 0.5 1 2 5 10
Favours azithromycin Favours tetracycline
Analysis 4.4. Comparison 4 Oral azithromycin versus topical tetracycline (individuals), Outcome 4 Ocular
C. trachomatis infection at 12 months.
Review: Antibiotics for trachoma
Comparison: 4 Oral azithromycin versus topical tetracycline (individuals)
Outcome: 4 Ocular C. trachomatis infection at 12 months
Study or subgroup Oral azithromycin Topical tetracycline Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dawson 1997 8/105 5/33 0.50 [ 0.18, 1.43 ]
0.1 0.2 0.5 1 2 5 10
Favours azithromycin Favours tetracycline
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Analysis 5.1. Comparison 5 Oral azithromycin versus control (communities), Outcome 1 Active trachoma
at 12 months.
Review: Antibiotics for trachoma
Comparison: 5 Oral azithromycin versus control (communities)
Outcome: 1 Active trachoma at 12 months
Study or subgroup Oral azithromycin Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Atik 2006 21/523 35/994 1.14 [ 0.67, 1.94 ]
TANA 2009 258/634 429/613 0.58 [ 0.52, 0.65 ]
0.01 0.1 1 10 100
Favours azithromycin Favours control
Analysis 5.2. Comparison 5 Oral azithromycin versus control (communities), Outcome 2 Ocular C.
trachomatis infection at 12 months.
Review: Antibiotics for trachoma
Comparison: 5 Oral azithromycin versus control (communities)
Outcome: 2 Ocular C. trachomatis infection at 12 months
Study or subgroup Oral azithromycin Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Atik 2006 23/659 68/1192 27.1 % 0.61 [ 0.39, 0.97 ]
Chidambaram 2006 51/513 82/408 30.3 % 0.49 [ 0.36, 0.68 ]
Lee 2007 2/170 56/185 10.2 % 0.04 [ 0.01, 0.16 ]
TANA 2009 88/600 282/618 32.4 % 0.32 [ 0.26, 0.40 ]
Total (95% CI) 1942 2403 100.0 % 0.35 [ 0.21, 0.60 ]
Total events: 164 (Oral azithromycin), 488 (Control)
Heterogeneity: Tau2 = 0.22; Chi2 = 19.95, df = 3 (P = 0.00017); I2 =85%
Test for overall effect: Z = 3.85 (P = 0.00012)
0.01 0.1 1 10 100
Favours azithromycin Favours control
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Analysis 6.1. Comparison 6 Oral azithromycin versus topical tetracycline (communities), Outcome 1
Active trachoma at 3 months.
Review: Antibiotics for trachoma
Comparison: 6 Oral azithromycin versus topical tetracycline (communities)
Outcome: 1 Active trachoma at 3 months
Study or subgroup Oral azithromycin Topical tetracycline Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
ACT 1999 Egypt 141/1050 199/775 0.52 [ 0.43, 0.64 ]
ACT 1999 Tanzania 343/1535 200/1042 1.16 [ 1.00, 1.36 ]
ACT 1999 The Gambia 38/818 48/782 0.76 [ 0.50, 1.15 ]
0.01 0.1 1 10 100
Favours azithromycin Favours tetracycline
Analysis 6.2. Comparison 6 Oral azithromycin versus topical tetracycline (communities), Outcome 2
Ocular C. trachomatis infection at 3 months.
Review: Antibiotics for trachoma
Comparison: 6 Oral azithromycin versus topical tetracycline (communities)
Outcome: 2 Ocular C. trachomatis infection at 3 months
Study or subgroup Oral azithromycin Topical tetracycline Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
ACT 1999 Egypt 10/1026 34/756 0.22 [ 0.11, 0.44 ]
ACT 1999 Tanzania 64/1510 64/1028 0.68 [ 0.49, 0.95 ]
ACT 1999 The Gambia 52/749 96/704 0.51 [ 0.37, 0.70 ]
0.01 0.1 1 10 100
Favours azithromycin Favours tetracycline
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Analysis 6.3. Comparison 6 Oral azithromycin versus topical tetracycline (communities), Outcome 3
Active trachoma at 12 months.
Review: Antibiotics for trachoma
Comparison: 6 Oral azithromycin versus topical tetracycline (communities)
Outcome: 3 Active trachoma at 12 months
Study or subgroup Oral azithromycin Topical tetracycline Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
ACT 1999 Egypt 149/1031 178/910 0.74 [ 0.61, 0.90 ]
ACT 1999 Tanzania 333/1351 191/925 1.19 [ 1.02, 1.40 ]
ACT 1999 The Gambia 58/675 82/522 0.55 [ 0.40, 0.75 ]
0.01 0.1 1 10 100
Favours azithromycin Favours tetracycline
Analysis 6.4. Comparison 6 Oral azithromycin versus topical tetracycline (communities), Outcome 4
Ocular C. trachomatis infection at 12 months.
Review: Antibiotics for trachoma
Comparison: 6 Oral azithromycin versus topical tetracycline (communities)
Outcome: 4 Ocular C. trachomatis infection at 12 months
Study or subgroup Oral azithromycin Topical tetracycline Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
ACT 1999 Egypt 30/1013 56/901 0.48 [ 0.31, 0.74 ]
ACT 1999 Tanzania 108/1327 73/909 1.01 [ 0.76, 1.35 ]
ACT 1999 The Gambia 53/636 66/490 0.62 [ 0.44, 0.87 ]
0.01 0.1 1 10 100
Favours azithromcyin Favours tetracycline
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A D D I T I O N A L T A B L E S
Table 1. Antibiotics: trial in individuals
Study Oral antibi-
otic
Oral antibi-
otic dose
Oral antibi-
otic sched-
ule
Oral antibi-
otic
comments
Topical an-
tibiotic
Topical an-
tibiotic
dose
Topical an-
tibiotic
schedule
Topical an-
tibiotic
comments
1 Attiah
1973
Tetracy-
cline
0.25% 1x daily for
11 weeks
School days
only
2 Bailey 1993 Azithromy-
cin
20 mg/kg single dose Not given
to pregnant
or lactating
women
Tetracy-
cline
1% 2x daily for
six weeks
People with
“severe dis-
ease” were
also
given ery-
thromycin
250mg
4x daily for
two weeks
3 Bowman
2000*
Azithromy-
cin
20 mg/kg single dose Tetracy-
cline
not
reported
2x daily for
six weeks
Unsuper-
vised
administra-
tion
4 Cochereau
2007
Azithromy-
cin
20 mg/Kg single dose Persons ac-
compa-
nying chil-
dren
enrolled
in the trial
were
treated
with oral
azithromy-
cin; soap
and
health edu-
cation pro-
vided
Azithromy-
cin
1.5% 2x daily for
2 days and
3 days
Persons ac-
compa-
nying chil-
dren
enrolled
in the trial
were
treated
with oral
azithromy-
cin; soap
and
health edu-
cation pro-
vided
5 Darougar
1980
Doxycy-
cline
5 mg/kg 1x monthly
for 12
months
Oxytetra-
cycline
1% 2x daily for
7 days, ev-
ery month
for 12
months
consecutive
days
6& 7 Dawson
1969
(Sherman
and
Trisul-
phapyrim-
idines
3.5 g 3x daily for
21 days
3 daily
doses to to-
tal 3.5g/day
Oxytetra-
cycline
1% 1 drop 4x
daily for 7
days, every
months for
consecutive
days
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Table 1. Antibiotics: trial in individuals (Continued)
Sterwart) 6 months
8 Dawson
1997*
Azithromy-
cin
20 mg/kg single
dose; single
dose weekly
for 3 weeks;
single dose
monthly
for six
months
three differ-
ent dosing
schedules
Oxytetra-
cycline/
polymyxin
1% / 10,
000 units
per g
1x daily for
5 days, ev-
ery month
for 6
months
9 Foster 1966 Sul-
phamethoxypyri-
dazine
500 mg/
day
1x daily for
5 days, ev-
ery week
for 3 weeks.
Tetracy-
cline
1% 3x daily for
5 days, ev-
ery week
for 6 weeks
10 Hoshiwara
1973
Doxycy-
cline
2.5-4.0
mg/kg
1x daily for
5 days, ev-
ery week up
to 28 doses
in 40 days.
11 Peach 1986 Tetracy-
cline
not
reported
daily for 5
days, every
month for
3 months
12 Shukla
1966
Sul-
phadimethox-
ine
100 mg/kg 2x weekly
or 1x
weekly, for
5 months
Sulphafu-
razole
15% 2x daily for
5 days, ev-
ery month
for 5
months
13 Tabbara*
1996
Azithromy-
cin
20 mg/kg single dose Tetracy-
cline
1% 2x daily for
5 days, ev-
ery week
for 6 weeks
14 Woolridge
1967
Tetracy-
cline
1% 2x daily for
6 days, ev-
ery week
for 6 weeks
* No untreated or placebo control group
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Table 2. Antibiotics: trials in communities
Study Oral
antibiotic
Oral
antibiotic
dose
Oral
antibiotic
schedule
Oral
antibiotic
comments
Topical an-
tibiotic
Topical an-
tibiotic
dose
Topical an-
tibiotic
schedule
Topical an-
tibiotic
comments
1,2& 3 ACT
(Egypt,
Tanzania
and The
Gambia)
Azithro-
mycin
20 mg/kg
up to 1g
once
a week for
three weeks
Pregnant
women
given ery-
thromycin
oxytetracy-
cline
1% once daily
for 6 weeks
4 Atik 2006 Azithro-
mycin
20 mg/
kg for chil-
dren; 1g for
adults
single dose Children
with active
trachoma
and house-
hold mem-
bers
treated;
Pregnant
women
given ery-
thromycin
tetracycline not
reported
not
reported
People
with active
trachoma
treated
5 Chi-
dambaram
2006
Azithro-
mycin
20 mg/
kg for chil-
dren; 1g for
adults
directly ob-
served
treatment.
single dose Pregnant
women,
children
younger
than 1 year,
and those
allergic to
macrolides
were
offered a 6-
week
course of
topical
1% tetracy-
cline oint-
ment (ap-
plied twice
daily to
both eyes,
not directly
observed)
6 Lee 2007 Azithro-
mycin
not
reported
not
reported
“Bian-
nual mass
azithromy-
cin treat-
ment of all
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Table 2. Antibiotics: trials in communities (Continued)
individ-
uals” aged
1 year or
more
7 Resnikoff
1995
oxytetracy-
cline
1% 1 drop 4x/
day
7 consecu-
tive days
per month
for six
months
8 TANA
2009
Azithro-
mycin
Height-
based dos-
ing to
roughly 20
mg/kg
single dose Women
self-
reporting
as pregnant
and chil-
dren aged
less than 1
year offered
topical
tetracycline
Table 3. Outcome reporting: trials in individuals
Study 3 months 3 months 12 months 12 months 24 months 24 months
Active
trachoma
Ocular
infection
Active
trachoma
Ocular
infection
Active
trachoma
Ocular
infection
1 Attiah 1973
√
H 1 H2 H2 H2 H2
2 Bailey 1993
√ √ √
(26 weeks)
√
(26 weeks) H2 H2
3 Bowman 2000
√
H3
√
H3 H2 H2
4 Cochereau
2007
√
E H2 H2 H2 H2
5 Darougar 1980
√ √ √ √
H2 H2
6 Dawson 1969
Sherman
√
H2 H2 H2 H2 H2
7 Dawson 1969
Stewart
√
H2 H2 H2 H2 H2
8 Dawson 1997
√ √ √ √
H2 H2
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Table 3. Outcome reporting: trials in individuals (Continued)
9 Foster 1966
√
H 1
√
H 1 H2 H2
10 Hoshiwara
1973
√ √
H2 H2 H2 H2
11 Peach 1986
√
H 1 H2 H2 H2 H2
12 Shukla 1966
√ √
H2 H2 H2 H2
13 Tabbara 1996
√ √
H2 H2 H2 H2
14 Woolridge
1967
√
H 1
√
H 1 H2 H2
ORBIT CLASSIFICATION (Kirkham 2010)
E: Clear that the outcome was measured but not necessarily analysed.
H: Outcome not mentioned but clinical judgement says unlikely to have been measured.
1. No mention of collection of laboratory samples in the paper.
2. No evidence of any data collection at this time point.
3. Study conducted on low budget therefore may not have been able to afford to collect lab specimens
Table 4. Outcome reporting: trials in communities
Study 3 months 3 months 12 months 12 months 24 months 24 months
Active trachoma Ocular
infection
Active trachoma Ocular
infection
Active trachoma Ocular
infection
1 ACT 1999
Egypt
√ √ √ √
H2 H2
2 ACT 1999 Tan-
zania
√ √ √ √
H2 H2
3 ACT 1999 The
Gambia
√ √ √ √
H2 H2
4 Atik 2006
√ √ √ √ √ √
5 Chidambaram
2006
Request to au-
thors for infor-
mation
√
(treatment
group only)
Request to au-
thors for infor-
mation
√ √
(treatment
group
only and control
group treated at
12 months)
6 Lee 2007 H3 H3 H4
√
H2 H2
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Table 4. Outcome reporting: trials in communities (Continued)
7 Resnikoff 1995
√
H 1
√
H 1 H2 H2
8 TANA 2009 Request to au-
thors for infor-
mation
F Request to au-
thors for infor-
mation
√
H5 H5
ORBIT CLASSIFICATION (Kirkham 2010)
F: Clear that outcome was measured but not necessarily analysed.
H: Outcome not mentioned but clinical judgement says unlikely to have been measured.
1. No mention of collection of laboratory samples in the paper.
2. No suggestion that study went on longer than 12 months.
3. Only 12 month examination appeared to have been conducted.
4. Paper did not report any clinical examination whilst this is unusual the focus of the study was “chlamydia on flies and children” so
it is possible that only laboratory samples were collected.
5. Control group treated at 12 months
Table 5. Adverse effects
Study Antibiotic (number treated) Report
1, 2 & 3 ACT 1999 (Egypt/Tanzania/The
Gambia)
Azithromycin (approx 3800)
Tetracycline (approx 2400)
No comment on adverse effects in re-
port
4 Atik 2006 Azithromycin and tetracycline (num-
bers treated difficult towork out exactly
but probably in the order of 100)
No comment on adverse effects in re-
port
5 Attiah 1973 Oxytetracycline (77)
Tetracycline derivative GS2989 (75)
No comment on adverse effects in re-
port
6 Bailey 1993 Azithromycin (97)
Topical tetracycline with oral ery-
thromycin in severe cases (97)
Table 2 on page 454 reports adverse ef-
fects. Abdominal pain reported more
often in azithromycin group (26% ver-
sus 16%, P = 0.09). Other effects: diar-
rhoea, vomiting, fever, headache, body
pain, other similar between two study
groups
“There were no serious adverse reac-
tions and both treatments were well tol-
erated. All symptoms resolved sponta-
neously and none required treatment.
” One study subject died, probably
due to malaria. He had received topical
tetracycline
7 Bowman 2000 Azithromycin (160)
Tetracycline (154)
No comment on adverse effects in re-
port
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Table 5. Adverse effects (Continued)
8 Chidambaram 2006 Azithromycin (approx 500 children) No comment on adverse effects in re-
port
9 Cochereau 2007 Azithromycin topical 2-day regimen
(222) 3-day (220 and oral azithromy-
cin (214)
“Ocular adverse events were reported
in 10.8%, 8.9% and 13.1% of pa-
tients in the 2-day, 3-day and oral treat-
ment groups respectively. Systemic ad-
verse events were reported in 2.6%, 10.
2% and 9.0% of patients. None of the
adveres events were treatment-related
events.On epatient (3-day group) had a
serious unrelated adverse events (death
due to head injury).” Page 670
10 Darougar 1980 Doxycycline (44)
Oxytetracycline (38)
No comment on adverse effects in re-
port
11 & 12 Dawson 1969 (Sherman/Stewart) Trisulfapyrimidines (33) “No untoward reactions to sulfon-
amides were noted” (page 587)
13 Dawson 1997 Oxytetracycline/polymyxin (43)
Azithromycin (125)
“In this trial, azithromycin was well tol-
erated and only two children (of 125
treated) complained of nausea” (page
367)
14 Foster 1966 Sulfamethoxypyridazine (112)
Tetracycline (106)
“3/155 students who received sul-
famethoxypyridazine had adverse re-
actions to the drug. One girl devel-
oped a severe purpura associated with
marked thrombocytopenia. She recov-
ered following withdrawal of the drug
and administration of corticosteroids.
Two cases of diagnosed drug rash ne-
cessitated discontinuance of the drug.
The nephrotic syndrome developed in
one boy three months after completion
of sulphonamide therapy, but the rela-
tionship of this development to therapy
was not determined. No reactions or
rashes occurred in the other two treat-
ment groups” (page 453) (note: Table
3/table 4 report 112 children treated
with sulphamethoxypyridazine)
15 Hoshiwara 1973 Doxycycline (49) “Anorexia, nausea, vomiting or diar-
rhea occurred in three childrenbetween
the 15th and 25th days of medica-
tion. Two of these children were re-
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Table 5. Adverse effects (Continued)
ceiving doxycycline, and the distur-
bances lasted only a single day in each
child, in spite of continuing medica-
tion. Between day 21 and 28 ofmedica-
tion, transient macular rashes and one-
day illness with low-grade fever and
anorexia occurred in four children.Two
of them had received drug, and two
placebo. It is likely that an intercur-
rent, unrelated illness was responsible.
Gross enamel dysplasia or tooth discol-
oration was not observed on examina-
tion 20 weeks after the end of medica-
tion.” (page 222)
16 Lee 2007 Azithromycin (8 villages treated, num-
ber individuals treated not reported)
No comment on adverse effects in re-
port
17 Peach 1986 Tetracycline (932) No comment on adverse effects in re-
port
18 Resnikoff 1995 Oxytetracycline (346) No comment on adverse effects in re-
port
19 Shukla 1966 Sulphafurazole (140)
Sulphadimethoxine (161)
No comment on adverse effects in re-
port
20 Tabbara 1996 Azithromycin (31)
Tetracycline (29)
“No adverse effects were noted” (page
844) and “The safety of a single oral
dose of azithromycin has been demon-
strated in this study. Similar to other
clinical studies, no adverse effects de-
veloped in any of the patients in the
azithromycin group” (page 845)
21 TANA 2009 Azithromycin (over 16,000 people
treated at baseline)
“We recorded no reported serious ad-
verse events attributed to study medi-
cation. 96 deaths were recorded in sub-
kebeles in the children-treated group
and 126 deaths recorded in those in
the control group. At 12 months a sur-
vey was undertaken to assess adverse
effects in the treated population (n=
671, 96 side-effects reported). [.. ] 56
(11.3%) patients reported abdominal
pain, vomiting, and nausea, whereas di-
arrhoea, constipation and related issues
accounted for 16 (2.4%) of complaints.
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Table 5. Adverse effects (Continued)
Four (0.6%) patients reported haemor-
rhoid or other as side effects” (House
et al page 1115). “In a trachoma-en-
demic area, mass distribution of oral
azithromycin was associated with re-
duced mortality in children” (Porco et
al, conclusion of abstract)
22 Woolridge 1967 Tetracycline (726)
Sulfonamide (526)
“No more than trivial reactions were
observed in any of these three studies,
to vaccine, to oil adjuvant , to eye oint-
ment or to sulfa drug.” (page 1581)
A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MeSH descriptor Trachoma
#2 MeSH descriptor Chlamydia trachomatis
#3 trachoma* or tracoma*
#4 (#1 OR #2 OR #3)
#5 MeSH descriptor Anti-Bacterial Agents
#6 antibiotic*
#7 MeSH descriptor Azithromycin
#8 azithrom*cin*
#9 MeSH descriptor Tetracycline
#10 tetracycline*
#11 MeSH descriptor Chlortetracycline
#12 chlortetracycline*
#13 MeSH descriptor Macrolides
#14 macrolide*
#15 (#5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14)
#16 (#4 AND #15)
Appendix 2. MEDLINE search strategy
1 randomized controlled trial.pt.
2 (randomized or randomised).ab,ti.
3 placebo.ab,ti.
4 dt.fs.
5 randomly.ab,ti.
6 trial.ab,ti.
7 groups.ab,ti.
8 or/1-7
9 exp animals/
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10 exp humans/
11 9 not (9 and 10)
12 8 not 11
13 exp trachoma/
14 trac?oma$.tw.
15 exp chlamydia trachomatis/
16 or/13-15 (14120)
17 exp antibacterial agents/
18 antibiotic$.tw.
19 exp azithromycin/
20 azithrom?cin$.tw.
21 exp tetracycline/
22 tetracycline$.tw.
23 exp chlortetracycline/
24 chlortetracycline$.tw.
25 exp macrolides/
26 macrolide$.tw.
27 or/17-26
28 16 and 27
29 12 and 28
The search filter for trials at the beginning of the MEDLINE strategy is from the published paper by Glanville (Glanville 2006).
Appendix 3. EMBASE search strategy
1 exp randomized controlled trial/
2 exp randomization/
3 exp double blind procedure/
4 exp single blind procedure/
5 random$.tw.
6 or/1-5
7 (animal or animal experiment).sh.
8 human.sh.
9 7 and 8
10 7 not 9
11 6 not 10
12 exp clinical trial/
13 (clin$ adj3 trial$).tw.
14 ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$)).tw.
15 exp placebo/
16 placebo$.tw.
17 random$.tw.
18 exp experimental design/
19 exp crossover procedure/
20 exp control group/
21 exp latin square design/
22 or/12-21
23 22 not 10
24 23 not 11
25 exp comparative study/
26 exp evaluation/
27 exp prospective study/
28 (control$ or prospectiv$ or volunteer$).tw.
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29 or/25-28
30 29 not 10
31 30 not (11 or 23)
32 11 or 24 or 31
33 exp trachoma/
34 trac?oma$.tw.
35 exp chlamydia trachomatis/
36 or/33-35
37 exp antibiotic agent/
38 antibiotic$.tw.
39 exp azithromycin/
40 azithrom?cin$.tw.
41 exp tetracycline/
42 tetracycline$.tw.
43 exp chlortetracycline/
44 chlortetracycline$.tw.
45 exp macrolide/
46 macrolide$.tw.
47 or/37-46
48 36 and 47
49 32 and 48
Appendix 4. metaRegister of Controlled Trials search strategy
trachoma and antibiotics
Appendix 5. ClinicalTrials.gov search strategy
Trachoma AND Antibiotics
Appendix 6. Changes made to data in the 2011 update of the review
Current review Original review
Treatment Control Treatment Control Comments
Com-
parison
Study n N n N n N n N
1.1 Ac-
tive tra-
choma
at 3
months
Peach
1986
216 340 138 189 284 408 182 233 Missing data counted
twice in original review
1.3 Ac-
tive tra-
choma
Wool-
ridge
1967
121 202 95 120 149 202 100 120 Error in data extraction
in original review
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(Continued)
at 12
months
2.1 Ac-
tive tra-
choma
at 3
months
Peach
1986
216 340 138 189 284 408 182 233 Missing data counted
twice in original review
2.3 Ac-
tive tra-
choma
at 12
months
Wool-
ridge
1967
121 202 95 120 149 202 100 120 Error in data extraction
in original review
3.1 Ac-
tive tra-
choma
at 3
months
Bow-
man
2000
48 152 68 139 56 158 83 156 People with missing
data counted as having
trachoma in original re-
view
3.1 Ac-
tive tra-
choma
at 3
months
Shukla
1966
53 83 29 62 53 83 34 42 Error in data extraction
in original review
3.1 Ac-
tive tra-
choma
at 3
months
Tabbara
1996
15 31 12 29 15 32 12 32 In the original review,
people who were not
followed up were in-
cluded in the denomi-
nator. This makes the
assumption that peo-
ple who were not fol-
lowed up had inactive
trachoma
3.2 Chlamy-
dia tra-
choma-
tis infec-
tion at 3
months
Tabbara
1996
6 30 4 26 Not included in previ-
ous review
3.3 Ac-
tive tra-
choma
at 12
months
Bow-
man
2000
32 149 45 139 Not included in previ-
ous review
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(Continued)
3.4 Chlamy-
dia tra-
choma-
tis infec-
tion at
12
months
Dawson
1997
8 105 5 33 7 105 5 33 Error in data extraction
in original review
5.1 Ac-
tive tra-
choma
at 12
months
Atik
2006
21 523 35 994 Not included in previ-
ous review
5.2 Chlamy-
dia tra-
choma-
tis infec-
tion at
12
months
Atik
2006
23 659 68 1192 Not included in previ-
ous review
5.2 Chlamy-
dia tra-
choma-
tis infec-
tion at
12
months
Lee
2007
2 170 56 185 Not included in previ-
ous review
ACT
study
Data for the ACT trial in the original review was not exactly the same as the published data and
included unpublished outcomes. The original review authors had access to individual patient data
which was not available to the current authors. In the absence of access to the original data, we felt
it was unwise to make any changes to the data included in the review.
Appendix 7. Results of searches for previous versions of the review
The original electronic searches identified 566 reports of studies, of which 51 reported antibiotic treatment trials for trachoma. A
total of 15 studies (8678 participants) met the inclusion criteria. Ten trials compared antibiotic to placebo or no treatment (Attiah
1973; Darougar 1980b; Dawson 1969i; Dawson 1969ii; Foster 1966; Hoshiwara 1973; Peach 1986; Shukla 1966; Tabbara 1988;
Woolridge 1967). One trial (Tabbara 1988) was later excluded as it was not possible to identify patient outcomes as both eyes of
the same patient were in some instances used in the randomisation and the results were reported as eyes not patients. The citations
Dawson 1969i and Dawson 1969ii refer to two arms of the same trial, which were conducted in different schools; as the results are
reported separately in the paper they have been treated as separate studies. Some of the above studies reported the comparison of
topical against oral antibiotics. A further six trials compared topical tetracycline to oral azithromycin (Bowman 2000; Dawson 1997;
Schachter 1999i; Schachter 1999ii; Schachter 1999iii; Tabbara 1996). The three Schachter 1999 citations used the same protocol but
applied in different countries and reported in the same article. Schachter 1999i refers to results from Egypt, Schachter 1999ii from
The Gambia and Schachter 1999iii from Tanzania. One further trial was excluded as an oral antibiotic, erythromycin, was used in
conjunction with topical tetracycline in severe cases of trachoma, the comparison being oral azithromycin (Bailey 1993b).
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The electronic searches were updated in 2005 and 206 new reports of studies were identified from the electronic searches. Hard copies
of two reports were obtained for further scrutiny. One study was excluded as the trial did not take place in a trachoma endemic region
(Isenberg 2002) and the other study by Humet 1989 was excluded as it did not assess the treatment of ocular Chlamydia trachomatis.
WH A T ’ S N E W
Last assessed as up-to-date: 11 December 2010.
Date Event Description
18 February 2011 New search has been performed Issue 3 2011: Electronic searches updated and 6 new
trials included. Risk of bias assessed for all studies and
summary of findings tables added
9 February 2011 New citation required and conclusions have changed Issue 3 2011: Review substantively updated. New au-
thorship.
H I S T O R Y
Protocol first published: Issue 3, 1999
Review first published: Issue 1, 2002
Date Event Description
31 March 2008 Amended Converted to new review format.
1 February 2005 New citation required and conclusions have changed Substantive amendment
C O N T R I B U T I O N S O F A U T H O R S
Original version of the review: Denise Mabey (DM) screened the search results, graded selected trials, extracted some data and wrote
the review. DM was the guarantor for the review. Nicole Fraser-Hurt (NF) graded selected trials, extracted the data and contributed to
writing the review.Chistine Powell screened the search results and worked on the update of the review.
Major update of review and change of authors 2011: JE and AWS screened search results, assessed the risk of bias of all included studies,
extracted data from new included trials and substantially rewrote the text of the review.
The Cochrane Eyes and Vision Group editorial team developed the search strategies and undertook the electronic searches.
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D E C L A R A T I O N S O F I N T E R E S T
The Edna McConnell Clark Foundation supported DM and NF for one half day a week over a 10 month period to undertake the
original review. SightSavers International part funded JE’s salary to update the review. AWS is a member of the International Trachoma
Initiative (ITI)’s Trachoma Expert Committee and has received research support from both ITI and Pfizer, the manufacturers of
azithromycin.
S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
External sources
• The Edna McConnell Clark Foundation, USA.
• Christian Blind Mission, Germany.
• Sightsavers International, UK.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
In 2011 this review was substantially revised. The major change was that we considered separately the individually-randomised and
cluster-randomised trials, and the Cochrane Collaboration’s tool for assessing risk of bias was implemented. The greater detail required
in Revman 5 format has meant that we have completed some aspects of the methods - such as assessment of heterogeneity - for this
update which were not discussed in detail in the original protocol.
N O T E S
This review was first published as Mabey D, Fraser-Hurt N. Antibiotics for trachoma. Cochrane Database of Systematic Reviews 2002,
Issue 1. Art. No.: CD001860. DOI: 10.1002/14651858.CD001860.pub2. The 2011 updated version has been written by a new
review team.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Chlamydia trachomatis; Administration, Oral; Administration, Topical; Anti-Bacterial Agents [administration & dosage; ∗therapeutic
use]; Azithromycin [administration & dosage]; Randomized Controlled Trials as Topic; Tetracycline [administration & dosage];
Trachoma [∗drug therapy]
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